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Acquire biopotential data from a region of
tissue to be stimulated

Perform a computational analysis of the
acquired biopotential data
Identify and place sufficient leads to provide a
number of possible conduction paths passing
in close proximity to the region of tissue of
interest

Dynamically control electrical signal delivery
to the region of tissue of interest by selectively
switching the use of the leads as conductors
and grounds

Vary stimulation intensity through one or more
external stimulation devices, including an
optical stimulation device, an electromagnetic
field-producing device, an electromechanical
stimulation device, and an audio stimulation
device.

Assess acquired data for the purpose of
subsequent altering of lead use
End

Fig. 20
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Acquire biopotential voltage data from a
region of tissue to be stimulated
Use biopotential voltage data to determine
parametric values of an electrical tissue
stimulation signal
Generate and apply to the region an electrical
stimulation signal with the determined
parametric values

Control signal application time by responding
to one or more parameters established through
analysis of empirical data, tissue electrical
properties, brain tissue EEG data, tissue
impedance, oxygen saturation, EMG activity,
electrocardiographic activity, biochemical
levels, respiration patterns, and/or an
arbitrarily set maximum time limit.

Fig. 21
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Measure the electrical properties of a region of
tissue to be stimulated

Compare the measurements statistically with
measures known to represent normal tissue
electrical properties in a normal healthy
population of living beings
Use data from the comparisons to determine
parametric values of an electrical tissue
stimulation signal

Generate and apply to the region an electrical
stimulation signal with the determined
parametric values

Fig. 22
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Measure biochemicals in tissues and fluids

relevant to the region to be stimulated

Analyze the measurements and determine
parametric values of an electrical tissue
stimulation signal in accordance with the
analysis.
Generate and apply to the region an electrical
stimulation signal configured to reduce tissue
impedance and increase depth of signal
penetration with the determined parametric
values

Fig. 23
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Place at least one stimulating lead in proximity
to each desired region of tissue
Place at least one ground lead in proximity to
each selected tissue region such that a vector
path extends between each stimulating lead
and each ground lead that passes through each
selected tissue region
Introduce an electrical stimulation signal
through at least one stimulating lead such that
current is caused to flow along the vector
path(s)

Using a stimulation switching circuit and

ground switching circuit coupled to a plurality
of leads, selectively cause the leads to serve as
either stimulation or ground leads in such a
way as to create multiple spatial paths of
electrical stimulation through tissues

Fig. 24
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Measure the electrical properties of a subject
Transmit the measurements to a remote
location over a network

Analyze the measurements at the remote
location

Remotely determine parametric values for an
electrical tissue signal in response to the
analysis
Transmit the parametric values over a network
to an electrical stimulation apparatus

Cause the electrical stimulation apparatus to
generate and apply an electrical stimulation
signal having the remotely determined
parametric values

Fig. 25
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Measure biophysical activity such as but not limited to EEG
and EMG in a portion of the body to be treated. (S1)
Compare the measured biophysical activity to normal
biophysical activity for that portion of the body. (S2)
Determine the site to which electrical stimulation will be

applied based on regions where the measured biophysical

activity differ from the normal biophysical activity. (S3)
Determine the stimulating signal's electrical parameters based
on the comparison of the measured biophysical activity to the
normal biophysical activity. (S4)

Place at least one stimulating lead in proximity to the
determined site. (S5)
Place at least one ground lead to create a vector between the
stimulating lead and the ground lead that passes through the
determined site. (S6)

Apply an electrical signal through the leads with the determined
electrical parameters. (S7)
Acquire information from a sensory input to quantify the
condition of the site being treated or the functional state of the
subject being treated, relatively concurrent with the application
of the electrical signal. (S8)

Alter at least one parameter of the electrical signal based on a
comparison of the information acquired from the sensory input
and a desired value in a normal subject. (S9)
End

Fig. 26
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Among other things, none of these patents discloses any

METHODS AND APPARATUS FOR
ELECTRICAL STIMULATION OF TSSUES
USING SIGNALS THAT MINIMIZE THE
EFFECTS OF TISSUE IMPEDANCE

consideration of the electrical nature of the tissues them

selves, either at the macro level or at the basic cellular level,

or of how tissue stimulation signals might be adapted to take
into account that electrical nature. At the macro level, a reduc

CROSS-REFERENCES TO RELATED
APPLICATIONS

This application is a Continuation-in-Part of U.S. patent
application Ser. No. 1 1/490,255 which is a continuation of
U.S. patent application Ser. No. 10/357,503 which claims
priority in an earlier filed provisional application U.S. Ser.
No. 60/353,234, filed on Feb. 4, 2002; this application also
claims priority in and incorporates by reference U.S. Provi
sional Patent Application Ser. No. 60/963,486 filed 6 Aug.
2007, U.S. Provisional Patent Application Ser. No. 61/014,
917 filed 19 Dec. 2007, and U.S. Provisional Patent Applica
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15

tion Ser. No. 61/024,641 filed 30 Jan. 2008, and U.S. Provi

sional Patent Application Ser. No. 61/032,241 filed 28 Feb.
2008.
BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to the field of pro
ducing and applying electrical energy to tissues for the pur
pose of stimulating Such tissues, and to therapeutic methods
and apparatus. More specifically, the present invention relates
to a system for providing and using electrical signals having
characteristics that allow them to minimize electrical imped
ance of tissues, and more specifically yet, to various methods
and apparatus for providing Such signals for the purpose of
providing therapeutic benefit to a living being.
2. Description of Related Art
A number of examples of recent patents may be used to
understand the background of the present invention, as well as
Some of the limitations it overcomes. For example, Boveja, et
al. in U.S. Pat. No. 7,076.307 disclose a method for pulsed
electrical stimulation of the vagus nerve as a means of pro
viding therapy for a number of neurological disorders. As
another example, Whitehurst, et al., disclose in several pat
ents (U.S. Pat. No. 7,013,177; U.S. Pat. No. 6,950,707; U.S.

25

30

35

40

SUMMARY OF THE INVENTION

Pat. No. 6,922,590; U.S. Pat. No. 6,901,294; and U.S. Pat.

No. 6,871,099) methods for treating a number of disorders
involving the application of electrical stimulation to the brain
and/or the spinal cord. In these patents, the method of delivery
for the electrical stimulation signal involves Surgically
implanting some device within the tissues. The disclosure of
King in U.S. Pat. No. 6,745,079 is yet another example of
teachings involving implantation for electrical stimulation.
However, King teaches the use of implantable electrodes

45

A tissue stimulation apparatus is provided comprising an
electrical stimulation device 1 that includes a stimulation

50

associated with an external device.

More general examples of patents exist that describe the
benefit of electrical stimulation of tissues. These examples
include the teachings of Carter (U.S. Pat. No. 6,853,863) and
Borkan (U.S. Pat. No. 6,662,053). In U.S. Pat. No. 7,054,686,
MacDonald discloses a process for stimulating tissue, such as
cardiac tissue, nerve tissue, and brain tissue, by delivering a
sequence of individual pulses. George, et al., disclose in U.S.
Pat. No. 7.024.239 a method ofusing electromagnetic energy
as a form of tissue stimulation for the purposes of treating
chronic wounds. Similar teachings exist for the use of elec
trical stimulation in speeding the healing process of wounds,
and in particular, to the repair process of injured bones (U.S.
Pat. No. 6,858,000 by Schukin, et al. and U.S. Pat. No. 6,678,
562 by Tepper, et al.).

tion of the fundamental impedance of tissues will have the
effect of providing for increased conductance and hence
deeper penetration of an applied electrical signal or field into
said tissues. At the cellular level, impedance changes simi
larly affect conductance, and also in the case of neural cells,
probably affect electrical properties such as nerve conduction
Velocity and neuron firing rates. As with all materials that
have the ability to conduct electricity, the impedance of tis
Sues involves components of both resistance and reactance.
Generally speaking, tissue is a relatively poor conductor of
electricity due to high resistance values. However, tissues
also have a capacitive nature that provides for a form of
impedance formally known as capacitive reactance.
Capacitive reactance decreases as the frequency of an elec
trical signal increases. This principle is the basis for the gen
eral knowledge that an ideal capacitor will completely block
a Zero-frequency signal (also known as a “DC signal) since
the capacitor's capacitive reactance will be infinite. Similarly,
the same capacitor will pose very little impedance to a signal
of very high frequency. Considering the capacitive nature of
tissues, higher frequency signals are more readily conducted
through them.
However, for the purposes of affecting tissues in a thera
peutic way, lower frequency signals are relevant. Thus, a
paradox exists in the pursuit of the use of electricity for
therapeutic purposes in that, while the low frequency signals
are useful for affecting tissues and biochemicals, they are also
most severely attenuated by tissue impedance.
The patents discussed above generally attempt to over
come this by using implantable devices that place the source
of the electrical stimulating energy in close proximity to the
tissues meant to be stimulated, or by providing stimulating
electricity at levels that are sufficiently high to allow for
attenuation and still accomplish an effect. In the latter case,
the comfort of the subject receiving the stimulation electricity
is frequently compromised during therapy.

55
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signal generation circuit configured to generate an electrical
tissue stimulation signal that reduces tissue impedance and
increases depth of signal penetration.
Also, a tissue stimulation method is provided, which com
prises the steps of providing a tissue stimulation apparatus
configured to dynamically alter the use of leads between
conducting biopotential Voltages, conducting an electrical
signal for stimulating tissues, and grounding, in response to a
computational analysis of biopotential data acquired from a
region of tissue to be stimulated; acquiring biopotential data
from a region of tissue to be stimulated; performing a com
putational analysis of the acquired biopotential data; in
response to the analysis, identifying and placing Sufficient
leads so as to provide a number of possible conduction paths
passing in near proximity to a region of tissue of interest; and
dynamically controlling electrical signal delivery to the
region of tissue of interest by selectively switching the use of
the leads as conductors and grounds.
A further tissue stimulation method is provided, which
includes the steps of determining parametric values of an
electrical tissue stimulation signal by obtaining biopotential

US 8,494,625 B2
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Voltage data from a region of tissue to be stimulated, and
determining parametric values of an electrical tissue stimu
lation signal in response to the biopotential Voltage data; and
generating and applying to the region of tissue an electrical
stimulation signal having the determined parametric values.
Another tissue stimulation method is provided, which
includes the steps of determining parametric values of an
electrical tissue stimulation signal by taking measures of
electrical properties of a region of tissue to be stimulated,
making statistical comparisons between the measures and
measures known to represent normal tissue electrical proper
ties in a healthy normal population of living beings, deter
mining parametric values of an electrical tissue stimulation
signal in response to the comparisons, and generating and
applying to the region of tissue an electrical stimulation signal
having the determined parametric values.
Another tissue stimulation method is provided, which
includes the steps of determining parametric values of an
electrical tissue stimulation signal by taking measures of

10

ated with abnormal levels of biochemicals in tissues. This
15

biochemicals from tissues and/or fluids relevant to the tissues

to be stimulated, analyzing the measures, and determining
parametric values of an electrical tissue stimulation signal in
accordance with the analysis of the measures. An electrical
stimulation signal having the determined parametric values
and configured to reduce tissue impedance and increase depth
of signal penetration is generated and applied to the region of

25

parameters.

method includes applying an electrical tissue stimulation sig
nal to a Subject Suffering from one or more conditions
selected from the group of conditions consisting of fibromy
algia syndrome, chronic fatigue, obesity, chronic pain,
muscle pain, myofascial pain, myofascial trigger points, and
psychological conditions, such as depression.
Also provided is a method for enhancing a body's own
healing mechanisms. This method includes applying an elec
trical tissue stimulation signal to a subject Suffering from one
or more conditions selected from the group of conditions
consisting of broken bones, injured tissues, post-Surgical
wounds, cuts, muscle pain associated with strains, and
Spasms.

tissue.

Also provided is a method of directing electrical stimula
tion signals through desired tissue regions. This method
includes the steps of placing at least one stimulating lead 21 in
proximity to the or each desired tissue region, placing at least
one ground lead 20 in another proximity to the or each desired
tissue region Such that a vector path extends between the or
each stimulating lead and the or each ground lead and passes
through the or each desired tissue region, and introducing an
electrical stimulation signal through the at least one stimulat
ing lead such that current is caused to flow along the or each
vector path through the or each tissue region between the or
each stimulating lead and the or each ground lead.
Also provided is a tissue stimulation method that includes
the steps of determining parametric values of an electrical
tissue stimulation signal by taking measures of electrical
properties of a Subject, transmitting the measures to a remote
location via a network, analyzing the measures at the remote
location, remotely determining parametric values of an elec
trical tissue stimulation signal in response to the analysis,
transmitting the parametric values from the remote location
via a network to an electrical stimulation apparatus, and caus
ing the electrical stimulation apparatus to generate and apply
to the region of tissue an electrical stimulation signal having
the remotely determined parametric values.
Also provided is a method for treatment of conditions using
electrical tissue stimulation signals, which includes the steps
of measuring biophysical activity in a portion of a subjects
body to be treated, analyzing the measured biophysical activ
ity, determining the or each site to which electrical stimula
tion will be applied, determining electrical parameters for the
electrical signal to be applied to the subject, which will tend
to bring the subject’s biophysical values for the determined
site to more normal, desired values, placing at least one stimu
lating lead in proximity to the or each determined site, placing
the or each ground lead so as to create a vector direction
between the or each stimulating lead and the or each ground
lead that will cause at least one path of electrical stimulation
to pass through the or each determined site, and applying
through the leads an electrical signal having the determined

4
Also provided is a method for treating conditions associ
ated with central nervous system dysfunction. This method
includes applying an electrical tissue stimulation signal to a
Subject Suffering from one or more conditions selected from
the group of conditions consisting offibromyalgia syndrome,
chronic pain, traumatic brain injury, affective disorders. Such
as attention deficit disorder (ADD) and attention deficit
hyperactivity disorder (ADHD), chronic fatigue, sleep disor
ders, obsessive compulsive disorder, Tourette Syndrome,
depression, anxiety, and addiction.
Also provided is a method for treating conditions associ

30

35

Also provided is a method for improving a body's function.
This method includes applying an electrical tissue stimula
tion signal to a Subject, the signal configured and applied in
Sucha way as to produce one or more effects selected from the
group of effects consisting of reducing fatigue, increasing
alertness, and increasing mental clarity.
Also provided is a method for enhancing performance
measures of a subject. This method includes applying an
electrical stimulation signal to a subject, the signal configured
and applied in Such a way as to enhance performance mea
Sures associated with one or more endeavors selected from

the group of endeavors consisting of athletic and academic
endeavors.
40

Also provided is a method for enhancing organ function in
a Subject. This method includes applying an electrical stimu
lation signal to a Subject, the signal configured and applied in
Such a way as to advantageously enhancing the function of an
Organ.

45

Additional advantages and novel features of the invention
will be set forth in part in the description that follows, and in
part will become more apparent to those skilled in the art upon
examination of the following or upon learning by practice of
the invention.

50

BRIEF DESCRIPTION OF THE DRAWINGS

55

For a more complete understanding of the present inven
tion, the needs satisfied thereby, and the features, and advan
tages thereof, reference now is made to the following descrip
tion taken in connection with the accompanying drawings.
FIG. 1 shows an apparatus constructed according to the
invention;

60

65

FIG. 2 shows a graphic representation of the neurostimu
lation signal;
FIG.3 shows a model of the apparatus of FIG. 1 in regards
to tissue impedance;
FIG. 4 shows another view of the apparatus of FIG. 1;
FIG. 5 shows a diagram of a high frequency signal, for use
in accordance with an embodiment of the present invention.
FIG. 6 shows a diagram of a low frequency signal, for use
in accordance with an embodiment of the present invention.

US 8,494,625 B2
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FIG. 7 shows a diagram of an amplitude modulated pulse
width modulated signal, for use in accordance with an
embodiment of the present invention.
FIG. 8 shows a diagram of a low frequency sinusoidal
signal, for use in accordance with an embodiment of the
present invention.
FIG. 9 shows a diagram of a sinusoidal amplitude modu
lated pulse width modulated signal, for use in accordance
with an embodiment of the present invention.
FIG. 10 shows a diagram of a low frequency composite
sinusoidal signal, for use in accordance with an embodiment
of the present invention.
FIG. 11 shows a diagram of a composite sinusoidal ampli
tude modulated pulse width modulated signal, for use in
accordance with an embodiment of the present invention.
FIG. 12 shows a diagram of an electrical stimulation appa
ratus, in accordance with an embodiment of the present inven

6
The term “optical unit is intended to define an apparatus
that is used on or in close proximity to the eyes. By close
proximity, it is meanta distance from the eyes of a Subject that
is effective for the transmittal of a light pulse into the eyes of
the subject. Preferably, close proximity will not exceed one
foot in distance from the subject. The structure of the optical
unit may be worn on the face of the patient, such as optical
device or goggles, or it may be located in a separate structure,
Such as a stand that is held near the face or even a hand-held
10

15

take.

tion.

FIG. 13 shows a diagram of an electrical stimulation appa
ratus, in accordance with an embodiment of the present inven
tion;

FIG. 14 shows a diagram of an electrical stimulation appa
ratus, in accordance with an embodiment of the present inven
tion;

FIG. 15 shows a diagram of an electrical stimulation appa
ratus, in accordance with an embodiment of the present inven

25

tion;

30

35

FIG. 19 shows a diagram of a mobile electrical stimulation
apparatus, in accordance with an embodiment of the present
invention;

FIG. 20 shows a flow diagram of method of applying
therapeutic electrical stimulation, in accordance with an
embodiment of the present invention;
FIG. 21 shows a flow diagram of method of applying
therapeutic electrical stimulation, in accordance with an
embodiment of the present invention;
FIG. 22 shows a flow diagram of method of applying
therapeutic electrical stimulation, in accordance with an
embodiment of the present invention;
FIG. 23 shows a flow diagram of method of applying
therapeutic electrical stimulation, in accordance with an
embodiment of the present invention;
FIG. 24 shows a flow diagram of method of applying
therapeutic electrical stimulation, in accordance with an
embodiment of the present invention;
FIG. 25 shows a flow diagram of method of applying
therapeutic electrical stimulation, in accordance with an
embodiment of the present invention;
FIG. 26 shows a flow diagram of method of applying
therapeutic electrical stimulation, in accordance with an
embodiment of the present invention;
FIG. 27 shows a diagram of a computer system, in accor
dance with an embodiment of the present invention.

40

45

50

55
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DETAILED DESCRIPTION

The present invention is directed towards a method and an
apparatus Suitable for the treatment of neurological dysfunc
tions.

The term “neurological dysfunction' is intended to define
a group of disorders in which one or more regions of a Sub
ject's brain operate at frequencies which are different from
the predetermined frequency for that region of the brain or
from the predetermined frequencies of the other regions of the
Subject's brain. Examples of neurological dysfunctions
include traumatic brain injury, post traumatic stress disorder,
post stroke paralysis, post traumatic brain injury paralysis,
cerebral palsy, headache, depression, post chemotherapy
cognitive, mood and fatigue disorder, fibromyalgia, memory
loss, coma, attention deficit disorder, etc. However, the

tion;

FIG. 16 shows a diagram of a Switching circuit, in accor
dance with an embodiment of the present invention;
FIG. 17 shows a diagram of an electrical stimulation appa
ratus, in accordance with an embodiment of the present inven
tion;
FIG. 18 shows a diagram of an electrical stimulation appa
ratus, in accordance with an embodiment of the present inven

mask. Further, the optic unit may be placed at an angle to the
eyes of the Subject. Additionally, the optic unit may be posi
tioned behind the subject and use mirrors or other reflective
devices (such as a white wall) to reflect the light pulse into the
eyes of the subject. However, in no way is this definition
intended to limit the ultimate structure the optical unit may
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present invention is not to be construed as being limited to the
treatment of these listed examples.
The term “irregular activity” is intended to define the EEG
frequency of an region of the Subject’s brain which does not
match the predetermined EEG activity of the remaining
regions of the subjects brain. Additionally, the term “irregu
laractivity” is also intended to define an EEG frequency of an
region of the subject's brain that matches the EEG activity of
the remaining regions of the Subject's brain, but with a high
degree of variance. Irregular activity is determined by ana
lyzing the frequency bands of the region of the brain being
investigated and identifying either a higher band amplitude or
a lower band amplitude than is predetermined for that region.
Examples of potential irregular activity include amplitude
abnormalities in which the measured peak-to-peak micro
volts is over 14 microvolts (abnormally high) or in which the
measured microvolts is under 5 Volts from peak-to-peak (ab
normally low) or possesses a standard deviation of over 3
microvolts. However, these are examples only. One of ordi
nary skill would recognize what a proper benchmark would
be for each subject.
The term “neurostimulation signal' is intended to define a
signal transmitted by the neurostimulator to a subject for the
purpose of normalizing the brainwave activity of regions of
the Subject's brain that possess irregular activity. The neuro
stimulation signal is determined on a subject by Subject basis
and is changed in relation to a shift in the region's dominant
frequency. There is typically a reduction in variability as EEG
changes occur. This is evidenced by a shift in the dominant
frequency more towards the typical frequencies and ampli
tudes that were predetermined for that region of the subjects
brain.
The term “normalization' is intended to define the result of

the administration of a neurostimulation signal to regions of
the subjects brain that correspond to the regions of the sub
ject's brain that possess irregular activity. The neurostimula
tion signal is intended to “normalize' or adjust the brainwave
frequency of the regions of the Subject's brain that possess
irregular activity to reflect the predetermined frequency of the
region of the subject's brain that is being treated.
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The term “dominant frequency’ is intended to define the
frequency in the EEG measurements taken from an area of the
Subject’s brain that possesses the highest Voltage amplitude.
The present invention is directed towards the alleviation of
symptoms of neurological disorders caused by irregular EEG
activity in a subject’s brain. The alleviation of the symptoms
is accomplished by administering a neurostimulation signal
to the regions of the subject’s brain that are related to those
regions of the Subject's brain that possess irregular activity.
These related regions of the subject’s brain can include
regions that possess irregular activity, or other regions of the
brain. One of skill in the neurological arts would recognize
which regions of the brain are interrelated with other regions
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of the brain.

For example, in one method of choosing the treatment
sites, the choice is determined by the regions of EEG-slowing
specific to an individual, regardless of the diagnosis. In this
method, it is the presence and pattern of EEG-slowing at any
of the standard neurological 10-20 sites (as selected by the
International 10-20 EEG Site Placement Standard) that is the
indication of the appropriateness of an region of the brain for
treatment. The EEG-slowing pattern also determines where
on the scalp electrodes will be placed for treatment.
Because EEG slowing that is associated with fatigue, poor
short-term memory, and attention problems is likely to
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involve functional deficits in the left frontal lobes of the

brains, placing electrodes on any of the following sites is a
reasonable directive: FP1, F7, F3, C3, F1, AF7, F5, AF3 and

possibly temporal sites, T3 & T5 (according to the Interna
tional 10-20 EEG Site Placement Standard). The amplitudes
and standard deviations from the image data determine the
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order of treatment for these sites.

The imaging data is preferably gathered by sequentially
recording from each of 21 sites. These data are preferably
processed through a Fast Fourier Transform (FFT) computa
tion which produces quantitative data that shows the average
microvolts and the standard deviation for each frequency
component of the EEG signal at each site. A preferred method
of treatment is to identify those sites that have the highest
standard deviation as shown in the FFT results and treat them

first. Treatment can be accomplished by placing two pairs of
electrodes (one positive and one negative comprise a pair) on
each of the four sites having the highest measured amplitudes.
It is the unique EEG pattern of the individual, however, that
is the key to the most efficient treatment. The determination of
treatment sites applies to any diagnostic category of neuro
logical dysfunction and the determination is individualized
by the quantitative data from each individuals brainwave
data. Therefore, it is not possible to specify a standard set of
sites for any given, or all, diagnostic categories. However,
there is a broad diagnostic classification called EEG-slowing
and that this category can permit the selection of predeter
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mined sites from which to direct the treatment of choice.

Therefore, given the above information one of ordinary skill
would understand how to select a region of the brain for
treatment on a Subject by Subject basis.
The neurostimulation signal is administered by modulat
ing a high frequency component, which can be further pulse
width modulated for control of the energy level, with a low
frequency carrier. It is the preferred intent of the present
invention to “disentrain the brain's electrical activity, that is,
to not target or lock into a particular frequency, but rather to
redistribute existing energy to all frequencies in the normal
spectra of the brain EEG in a typically uniform manner.
However, the present invention does not preclude the utiliza
tion of the neurostimulation signal for the purposes of
entrainment.
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The present invention also embodies a method of focusing
a neurostimulation signal directly on a suspected dysfunc
tional region of the brain. This is possible because tissue
impedances are minimized by the design of the neurostimu
lation signal. The neurostimulation signal possesses a greater
ability to directly reach damaged regions of the brain rather
than simply following the outer-most tissues around the scalp
and thereby bypassing the damaged region of the brain.
Another advantage is achieved by inducing the neurostimu
lation signal directly into EEG sensors. This advantage is that
the neurostimulation signal can be strategically placed to
present a conduction path through the damaged region of the
brain, while concurrently measuring the EEG signal at the
dysfunctional regions, thus providing a direct link between
the measured EEG signals and the neurostimulation signals
being delivered directly to the dysfunctional region.
A method for treating a subject with the method of the
present invention preferably includes the generation of an
electrical neurostimulation signal characterized by a high
frequency pulse train modulated by a low frequency carrier
signal. A means of providing for variable levels of electrical
power may be accomplished by using either pulse width
modulation of the high frequency pulse train, as in the pre
ferred embodiment of the present invention, or variable
amplitudes of the same pulses. Preferably, the frequency of
the high frequency pulse train is at least one order of magni
tude greater than the frequency of the low frequency carrier
signal. It is preferred that the high frequency pulse be in the
range of 43 to 1,000,000 hertz. It is more preferred that the
high frequency pulse be in the range of 1,000 to 100,000
hertz. It is even more preferred that the high frequency pulse
be in the range of 10,000 to 20,000 hertz. It is most preferred
that the high frequency pulse be 15,000 hertz.
The low frequency carrier signal is variably related to
critical frequency components of the EEG power spectral
density, determined from statistical analysis of amplitudes
and variability. The low frequency carrier signal is deter
mined from information obtained by measuring EEG activity
at a reference site or sites that generally corresponds with the
location of suspected brain dysfunction, and the low fre
quency carrier signal is dynamically changed as a function of
time to prevent entrainment. This is performed by changing
the frequency offset (as described below) at predetermined
time intervals. It is preferred that the low frequency carrier
signal be typical of a brainwave EEG. It is more preferred that
the low frequency carrier signal be in the range of 1-42 hertz.
The combination of (1) the high frequency pulse train as it
is modulated by (2) the low frequency carrier signal, hence
forth referred to as an AMPWM signal, provides a means of
minimizing the effect of tissue impedances of the head. How
ever, no limitation of the present invention to AMPWM sig
nals alone is intended by this abbreviation. Any signal that
possess both (1) and (2) as defined above is intended to be
encompassed by the present invention.
In general, as will be discussed in greater detail in Subse
quent sections of this disclosure, the electrical impedance of
tissues of the head decreases with increased electrical signal
frequency. Thus, the high frequency pulse train component of
the AMPWM signal passes through the head tissues with less
attenuation than the low frequency carrier signals typically
used in already known neurostimulation methods. Further,
the low frequency carrier signal component of the neuro
stimulation signalinessence serves to turn on and off the high
frequency signal component with a frequency that is gener
ally related to the range of frequencies present in an EEG
signal. Thus, the low frequency carrier signal component may
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be produced at frequencies commonly used for therapeutic
purposes in neurostimulation devices, such as entrainment or
disentrainment.

Some neurological dysfunctions that may be treated by the
present invention include traumatic brain injury, post trau
matic stress disorder, post stroke paralysis, post traumatic
brain injury paralysis, cerebral palsy, headache, depression,
post chemotherapy cognitive, mood and fatigue disorder,
fibromyalgia, memory loss, coma, attention deficit disorder,
etc. However, this list is not intended to be exclusive.

The method preferably comprises taking a first measure
ment of the EEG of a subject afflicted with at least one type of
the neurological dysfunction in order to obtain EEG results
and evaluating the obtained EEG results to determine whether
any region of the Subject’s brain possesses irregular activity
as compared to other regions of the Subjects brain. It is
preferred that the subject be a mammal and, more preferably,
a primate. It is most preferred that the subject be a human
being. It is also preferred that the irregular activity be deter
mined by comparing the EEG signals from a region of the
subjects brain with the EEG signals from the remaining
regions of the subjects brain. It is also preferred that the EEG
signals are obtained from more than one region of the Sub
jects scalp. It is even more preferred that the EEG signals be
obtained from at least 21 regions of the subject’s scalp that
correspond to 21 regions of the subjects brain. It is preferred
that the regions be selected according to the International
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10-20 EEG Site Placement Standard.

A determination of a dominant frequency of the Subjects
brain is made from the evaluating the EEG results from the
regions of the subject’s brain that possess irregular activity.
Preferably, the evaluation involves the correlation of the EEG
signals into a graphic image of the Subject's brain. Even more
preferably, the graphic image is evaluated and new EEG
signals from the Subject's brain are taken in order to ensure
that the first EEG signals were accurate and in order to deter
mine a dominant frequency from the regions of the Subjects
brain that have been confirmed as possessing irregular activ
ity.
Finally, the method comprises an administration of an anti
neurological dysfunction therapy to the Subject. The anti
neurological dysfunction therapy comprises inducing a neu
rostimulation signal directed to the regions of the Subjects
brain that possess irregular activity for a time Sufficient to
normalize the EEG signals of the regions of the subjects
brain that possess irregular activity.
It is preferred that the time be between one second and one
hour. It is more preferred that the time be between 1 and 30
minutes. It is even more preferred that the time is between 1
minute and 10 minutes. It is even more preferred still that the
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time be between 1 minute and 3 minutes. It is still more

preferred that the time be between 1 second and 30 seconds.
It is most preferred that the time be between 1 second and five
seconds.

Additionally, further EEG signal measurements from the
regions of the Subject's brain that possess irregular activity
are monitored during the administration of the therapy and the
neurostimulation signal is adjusted based on any detected
changes in the additional EEG signal measurements. The
normalization of the EEG signals from the regions of the
Subject’s brain that possess irregular activity results in an
alleviation of the symptoms of the neurological disorders.
The neurostimulation signal comprises a carrier frequency
which comprises the dominant frequency and the frequency
offset. It is preferred that the frequency offset be between -10
and 20 hertz.
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It is preferred that the normalization of the regions of the
Subject's brain that possess irregular activity result in these
regions transmitting EEG signals which are close to the pre
determined frequency and amplitude expected for those
regions of the subjects brain. It is even more preferred that
these regions transmit EEG signals at the predetermined fre
quency and amplitude expected for those regions of the Sub
ject's brain after the treatment.
The Subject may require multiple exposures to the method
in order to achieve an alleviation of the symptoms he or she
suffers from the neurological dysfunctions. It is preferred that
the multiple exposures remain in the range of 1 to 40 expo
Sures. However, more exposures are permitted, if required. It
is more preferred that the exposures remain in the range of 10
to 30 exposures. It is more preferred that the exposures remain
in the range of 5 to 10 exposures. Additionally, it is preferred
that a repeated use of the method be avoided within 24 hours
of a previous use of the method. However, if required, it is
possible to treat more than one region of the subject’s brain (if
more than one region of the Subjects brain possesses irregu
lar activity) in one treatment session.
Additionally, the Subject may be medicated, sedated, or
unconscious during the administration of the method. How
ever, it is preferred that the subject be in none of these con
ditions.

Regarding the application of the neurostimulation signal
itself, after the identification of regions the subjects brain
which possess irregular activity, neurostimulation treatment
is accomplished by placing EEG sensors in an arrangement
that allows for the measurement of the EEG activity from the
dysfunctional region, as well for providing a Successful deliv
ery of current from the EEG sensors into a system ground.
The computer-controlled system in the preferred embodi
ment of the present invention acquires EEG signal data from
the sensor sites and conducts an analysis of the EEG signal
data to determine the frequency of the low frequency carrier
signal component of the AMPWM signal.
The AMPWM signal can be transmitted to the subject
through a plurality of neurostimulation delivery modes. In a
preferred embodiment of the present invention the preferred
mechanism of delivery is accomplished by inducing the
AMPWM signal into the EEG sensors through inductive cou
pling. Another preferred mechanism is to use the AMPWM
signal to drive a light-generating component. Such as a light
emitting diode, to provide a photic stimulation signal that
may be delivered to the patient through the optic nerve.
Another preferred embodiment involves the simultaneous
use of stimulation delivery by inducing the AMPWM signal
into the EEG sensors through inductive coupling and drive a
light-generating component, such as a light emitting diode, to
provide a photic stimulation signal. In essence, this is a com
bination of previously discussed embodiments.
Lastly, it is preferred that EEG leads be placed on the scalp
regardless of what stimulation method is used because the
apparatus and method preferably measures EEG during
stimulation delivery, and uses these EEG measurements to
drive neurostimulation signal parameters.
In a preferred embodiment of the present invention, deliv
ery mode is selectable to account for different levels of sen
sitivity and tolerance in patients. It is also possible to com
pletely automate the process of transmitting the
neurostimulation signal and the monitoring of the EEG signal
data from the EEG sensors.
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As stated above, it is preferred that the EEG signals from
the subject be measured at typically 21 different scalp loca
tions and it is preferred that power spectral density computa
tions are performed on the obtained EEG signals. These com
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putations break the measured analog EEG signals into
frequency domain data such as a Fourier series of discrete
frequency components, which is limited to 1-42 Hertz
(greater signal components exist and could be utilized, but the
1-42 Hertz range is typically considered clinically useful).
However, other methods of obtaining the frequency domain
data are acceptable (such as the use of wavelet analysis).
In analyzing EEG signal data, frequency bands are com
monly used. For example, the “delta” band is typically 1-4
Hertz, the “theta' band is 5-7 Hertz, and so on. For each site,

the total amplitude associated with each discrete frequency
component is assigned to proper bands, providing a measure
of the EEG band energy for each of the aforementioned sites.
From this, a graphic “image' is generated where colors rep
resent amplitudes. From this image, the clinician can see EEG
band activity related to regions of the brain, and based on
clinical knowledge, can determine if a region has unusual or
abnormal activity.
Accordingly, the neurostimulation phase of the process
(i.e. treatment) is administered to correct regions of abnormal
activity. The administration of the neurostimulation signal is
preferably performed after the imaging process described
above is completed. The clinician preferably applies EEG
sensors to regions of the Scalp that relate to the regions of
suspected dysfunction and the EEG signal data is preferably
re-measured for a period long enough to provide power spec
tral density data (as in the imaging process). The frequency
domain data is then sorted, and the frequency that exhibits the
highest amplitude is designated the "dominant frequency’.
According to clinician chosen stimulation time and frequency
parameters, a neurostimulation signal is generated that has a
“carrier frequency” that is determined by the formula: CAR
RIER FREQUENCY=DOMINANT FREQUENCY+FRE
QUENCY OFFSET.
The parameters the clinician uses are (1) stimulation inten
sity, (2) the times that the stimulation signal is turned on in the
treatment cycle (as well as the number of times), (3) the
duration that each stimulation signal is turned on, the leading
frequency of each stimulation event, and (4) the phase offset
of each stimulation event. Intensity is defined by the pulse
width-modulation duty cycle, and ranges from 0 (no "on
time') to 100% (no “off-time'). Thus, an intensity of 50%
would have a duty cycle such that “on-time' is equal to
“off-time' in each pulse cycle. The number of stimulation
cycles and the times that the stimulation turns on is entirely
clinician driven. However, it is preferred ranges that the
stimulation cycles range between 1 Stimulation event up to
50. It is preferred, however, that no more than 20 different
stimulation events be used per session. The preferred leading
frequency is already defined to range between -10 and 20 Hz.
Preferred Phase offset ranges from -180 to 180 Hz.
In this formula, “frequency offset is preferably selected
from the range of -40 to 40 Hertz and more preferably from
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Duration. This is a measure the time in seconds that a
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-10 and 20 Hertz.

The offset is chosen by clinical experience, therefore, one
of ordinary skill in the art would recognize how to choose an
offset. However, the clinician generally picks the largest off
set (i.e., +20 Hz) to see ifa response is elicited. If no response
is elicited, lower offsets will be tried until a response is
obtained. The clinician’s choice of parameter values is typi
cally driven by a selection of choices that cause the subject to
react, but yet do not cause an “over-reaction' which is an
adverse effect characterized by short-term fatigue, headache,
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All of the preferred neurostimulation parameters to be
considered are defined below. Values of these parameters are
chosen based on clinician experience, and are selected in a

12
manner that is meant to cause a reactive therapeutic effect
without causing the subject to over-react. The selection of
these values is further driven by subject condition and symp
tomatic presentation. For example, a Subject with mild trau
matic brain injury may be able tolerate a longer (in duration)
than average stimulation application without Suffering an
adverse effect. However, a subject with fibromyalgia with
severe fatigue may only tolerate a very short (in duration)
stimulation burst at the lowest intensities possible. The ranges
of values for these parameters are provided for the clinician to
choose based on experience, patient condition and symptom
atic presentation, thus no preferred or optimal values exist.
These parameters include:
Intensity. This is a measure of the pulse width modulation
signals duty cycle. This provides a variation on the time
averaged current delivered to the stimulation mechanisms
(i.e. the EEG lead inducing circuit and the photic stimulators).
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neurostimulation event (i.e. a period of stimulation signal
output) lasts. This can range from 1 second to 1,200 seconds
in the preferred embodiment.
Start Time This is the time in seconds after the beginning
of a neurostimulation treatment session begins when a neu
rostimulation event starts to occur. There is no specific limi
tation on this, that is, the start time could begin at any time
after the treatment session begins. Before the start time
occurs, the system is simply measuring EEG and this could,
theoretically, go on indefinitely.
Leading Frequency and Phase Offset are previously
defined.

By adding the frequency offset to the dominant frequency,
a carrier frequency is created that is always different than the
dominant frequency. This neurostimulation signal is then
either induced in the EEG sensors attached to the subjects
Scalp or the neurostimulation signal is used to drive light
emitting diodes for photic stimulation purposes. The duration
of the signal, along with other parameters (as described
above) such as intensity and phase offset (in the case of LEDs
for photic stimulation—a phase offset causes the LEDs to
flash out of synchronization with each other) are determined
by the clinician's chosen treatment protocol.
As described above, the neurostimulation signal can be an
amplitude modulated pulse-width modulation signal. A
graphic representation of the signal is shown in FIG. 2. In
other words, the carrier frequency simply turns an electric
signal on and offin a way that a square-wave pulse train is
generated with a frequency equal to the carrier frequency.
Thus, in a period (period=1/frequency) of this pulse train,
there will be an amount of time that the electric signal is “on”
and an amount of time when the signal is “off” (see FIG. 2).
During the time that the carrier signal is “on”, the electricity
is further pulsed at a very high frequency. A pulse width
modulator is used to control this high frequency pulsing. By
varying the pulse width, the average current applied is varied.
This is what varying the “intensity” means. With a very low
duty cycle, there is very little average current and thus the
neurostimulation signal has very low intensity. Conversely, a
higher duty cycle delivers more current and thus the intensity
increases. A 100% duty cycle means that there is no “high
frequency off time', and thus the entire neurostimulation
signal is a simple square wave pulse train with frequency
equal to the carrier frequency.
Regarding the apparatus, FIG. 3 presents a model of the
apparatus of the present invention. In FIG. 3, tissue imped
ance 6 is represented by a parallel combination of a simple
resistor 1 and a simple capacitor 2. A Voltage source 3 pro
vides electricity at a supply electrode 4 interfaced at a sub
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jects skin 7, with the electricity passing through the tissue
impedance 6 and ultimately being returned to a common
ground 5 potential. Following fundamental circuit analysis,

the equivalent impedance (Zor-Evr) of the circuit is
given by the formula:

ZEQUIVALENT = 1 + 2fRC
10

In this formula, the resistance is given by the nomenclature
R, capacitance by C and frequency by f. This equation clearly
shows that as the frequency of the signal increases, the overall
impedance of the system decreases despite the level of imped
ance from the resistor 1 being constant. Although the imped
ances of the composite tissues of the head are considerably
more complex and require a far more Sophisticated model to
accurately describe current flows, this model provides a
simple analogy and approximately describes the effect, and is
a fundamental basis for the disclosure of the present inven
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tion.

The effects of applying electrical energy to brain tissues,
the electrical energy is known in this disclosure as a neuro
stimulation signal, are well established in the medical litera
ture and in other teachings, and will not be expounded upon
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into the inductor, which further induces electrical current in

here.

As stated above, the invention is also directed to an appa
ratus for neurostimulating a Subject. The apparatus comprises
a computing device that is operatively coupled to a neuro
stimulator, and a series of EEG sensors that are coupled to the
neurostimulator. Examples of appropriate computing devices
are microprocessors or computers. However, any processing
unit can be used in the present invention as a computing
device. These components are coupled to each other via elec
trical conduction paths. For example, the neurostimulator
could be coupled to the computing device with RS232 cable,
USB cable, etc. Further, the EEG sensors can be coupled to
the neurostimulator with an electrical connector. However, in

both instances, other methods of coupling the components are
acceptable. The EEG sensors are configured (1) to be attached
to the subject, (2) to monitor EEG signals of a subject, and (3)
to administer neurostimulation signals to the Subject. Addi
tionally, the EEG sensors comprise at least one positive con
tact, at least one negative contact, and at least one ground
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the EEG sensors via electromagnetic coupling, and thereby
into the subject.
The neurostimulator can further comprise an optical unit
which further comprises a set of light generating devices
located in close proximity to the pupils of the subject. It is
preferred that the light generating devices are light-emitting
diodes.
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With reference to the accompanying FIG. 1, a preferred
embodiment of the present invention is described where a
computing device 8 is operatively coupled to a peripheral
device henceforth referred to as a neurostimulator 9, such as

40

through a peripheral cable 10. However, a peripheral cable is
not the only method of coupling the neurostimulator to the
computing device. The neurostimulator 9 further comprises a
series of electrical conductors henceforth referred to as EEG
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sensors 11. The EEG sensors 11 consist of at least one positive
lead 12, one negative lead 13 and one ground lead 14. How
ever, the at least one positive lead 12, one negative lead 13.
and one ground lead 14 may also be incorporated into one
SenSOraS COntactS.

COntact.

The apparatus further comprises a biopotential acquisition
device, at least one filtering unit, an isolation amplifier, and a
microcontroller. A preferred microcontroller is the Toshiba
TMP95EY64. However, any comparable microcontroller
may be used. The biopotential device is operatively coupled
to the computing device, and the neurostimulator is config
ured to transmit the biopotential data and EEG signal data to
the biopotential acquisition device. These components may
be coupled together in the manner set forth previously or in
any additional manner that permits their correct usage. Addi
tionally, the biopotential acquisition device is configured to
transmit the EEG data and biopotential data through at least
one circuit or numerical filter and through an isolation ampli
fier which is operatively coupled to the microcontroller. Fur
thermore, it is preferred that the isolation amplifier be capable
of performing “notch' filtering (i.e., eliminate 60 Hz line
noise) and it can be selected from any component found on
the market. It is preferred that it be a Burr-Brown ISO-100.
It is preferred that the filtering unit be selected from the
group consisting of a circuit configured to filter data and a
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numerical filter. It is also preferred that the biopotential acqui
sition device is a biopotential amplifier or a high resolution
analog-to-digital converter.
The neurostimulator comprises a biopotential acquisition
unit comprising an electric circuit configured to acquire bio
potential data from the EEG signals obtained by the EEG
sensors attached to the Subject. The biopotential acquisition
unit is also configured to analyze and store the acquired
biopotential and EEG data with computational means and it is
operatively coupled to the neurostimulator. The neurostimu
lator also comprises a transmission unit configured to trans
mit the biopotential and EEG data from the neurostimulator
to the computing device and an I/O (input/output) unit con
figured to adjust for a time lag in the biopotential and EEG
data being transmitted. The neurostimulator also comprises at
least one Switching unit configured to manage a neurostimu
lation signal.
It is preferred that the subject is a mammal. It is further
preferred that the subject be a primate and even more pre
ferred that the subject is a human being. It is also preferred
that the Switching device is a transistor.
Additionally, the neurostimulator comprises an inductor,
acting as a transformer, whereas the stimulation signal is
induced in the neurostimulator by inducing electrical current
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In a preferred embodiment of the present invention,
employing multiple sets of EEG sensors II simultaneously
and multiple biopotential acquisition devices 15 can accom
plish acquisition of EEG signals from multiple sites on the
scalp. For clarity, the preferred embodiment is described with
for acquisition of EEG signal from one scalp site. All EEG
sensors 11 are connected to the neurostimulator 9 via EEG
sensor connectors 17.
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The neurostimulator 9 can further comprise, as a possible
means of delivering the stimulation signal, an optical unit 16
that is electrically coupled to the neurostimulator 9 via optical
device sensors connectors 19. The optical unit 16 can be
connected to the neurostimulator 9 by an optical device cable
18. However, other means of connecting the optical unit to the
neurostimulator are acceptable. The optical device further
comprises light generating devices 20 located to be in close
proximity to the subject’s eyes. In the preferred embodiment,
the light generating devices 20 are light emitting diodes 21.
The neurostimulator 9 is operated by any number of pos
sible power Supply 22 Sources. To assure electrical isolation
for the patient’s safety, an isolated power supply 23 is utilized
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in the preferred embodiment. Further, the neurostimulator 9 is
housed in a protective outer enclosure 24.
The neurostimulator 9 preferably internally comprises the
biopotential acquisition device and the biopotential acquisi
tion device is preferably designed to acquire biopotential data
from EEG signal data, specifically patient EEG, to provide a
means for analysis and data storage of the biopotential data
through computational means, generate a neurostimulation
signal and deliver the neurostimulation signal to the patient. It
is preferred that a Teledyne A110-2 amplifier be used.
In a preferred embodiment of the present invention, EEG
signals are acquired with EEG sensors 11 attached to a
patient’s scalp. At the end of the EEG sensors 11 attached to
the patient are contact electrodes 25. The EEG signal is deliv
ered to the neurostimulator 9 via the EEG sensors 11, con

nected to the biopotential acquisition device 15 through EEG
lead connectors 17 and operatively coupled to a biopotential
acquisition device 15 Such as a biopotential amplifier or high
resolution analog-to-digital converter. To minimize the effect
of external electrical noise, any number of circuit or numeri
cal filters 26 may be employed in the preferred embodiment.
To assure patient safety, the biopotentials are passed through
an isolation amplifier 27. The output of the biopotentials, after
passing through the biopotential acquisition device 15, filters
26 and isolation amplifier 27 is acquired by a microcontroller
28 through analog-to-digital ports 29. The microcontroller 28
is operatively coupled to the computing device 8. One method
of coupling the microcontroller to the computing device is to
use a peripheral cable 10. Control of the neurostimulator 9 is
accomplished by communication between the microcontrol
ler 28 and the computing device 8. Further, the objective of
biopotential data analysis and storage is accomplished com
putationally via communication between the microcontroller
28 and the computing device 8.
After analysis of the acquired biopotential, that is, the EEG
signal, the computing device 8 communicates proper stimu
lation signal parameters, in accordance with the present
invention, to the microcontroller 28. These parameters
include signal energy level, frequency of the low frequency
component of an AMPWM signal, phase offset of multiple
signals, start time, frequency offset and duration through a
user interface. Utilizing a digital-to-analog port 30 on the
microcontroller 28, the stimulation signal is output from the
microcontroller 28 to transistors 31 or similar switching
devices capable of managing the current levels of the stimu
lation signal. Depending on the mode of Stimulation chosen
by a clinician, the stimulation signal will be routed to the
different means of stimulation signal delivery, alone or in
combination. The parameters for the clinician’s choice are set
forth above.

If optical stimulation is desired, the stimulation signal will
be sent to the optical unit 16 featuring the light generating
devices 20 to be worn by the patient. Any unit capable of
emitting light may be used as a light generating device. This
includes, but is not limited to a LED, a lightbulb, a low-power
laser, etc. Alternately, if EEG lead 11 stimulation is desired,
where the stimulation signal is delivered to the patient's scalp
via the attached electrodes 25, then the stimulation signal is
sent to an inductor 32 which is designed to induce current in
the EEG sensors 11 from the stimulation signal generated by
the microcontroller 28. In the preferred embodiment of the
present invention, a plurality of stimulation delivery modes is
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Alternately, for photic stimulation, the isolated power Sup
ply 23 is preferably coupled via electrical coupling to two
more transistors 31, which are preferably operatively coupled
via electrical coupling to independent digital-to-analog ports
30 on the microcontroller 28. Electricity conducted from the
digital-to-analog ports 30 to the base of the transistors 31 in
the photic stimulation circuit has the effect of switching on
these transistors, further allowing for conduction of electric
ity to the photic stimulation devices, such as LEDs 21. The
photic stimulation devices are preferably coupled to the tran
sistors 31 via electrical connectors 19, thus providing for
current flow to the photic stimulation devices such as LEDs
21.
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warranted to allow for clinician choice to further effect suc

cessful treatment based on individual patient needs.
To assure patient safety, all electronics in the neurostimu
lator 9, including the biopotential acquisition device 15, the
filter 26, the isolation amplifier 27, the microcontroller 28 and

16
the transistors 31 are supplied electricity by the aforemen
tioned isolation power supply 23.
Finally, regarding the coupling of the components, if a
computing device is used it is preferably operatively coupled
to the processor of the neurostimulator via any of a number of
means of commonly used peripheral communications tech
niques, such as serial communication, USB port communi
cation or parallel communication 10. All remaining electron
ics are preferably operatively coupled to the processing
device (e.g. microcontroller) in the neurostimulator. The data
acquisition circuit preferably comprises the biopotential
acquisition device 15, filters 26 and isolation circuitry (ampli
fier) 27. The isolation amplifier is preferably coupled to an
analog-to-digital input port on the microcontroller 28, via
electrical conduction paths. Such as wires or printed circuit
board conductors. The filters 26 are preferably operatively
coupled to the isolation amplifier 27 via electrical conduction
paths such as wires or printed circuit board conductors. Fur
ther, the biopotential acquisition device 15 is preferably
operatively coupled to the filters 26 via electrical conduction
paths such as wires or printed circuit board conductors.
EEG leads 11 are preferably coupled to the biopotential
acquisition device 15 via electrical connectors 17, providing
conduction of EEG electricity at the scalp to the biopotential
amplifier 15.
A stimulation circuit is preferably coupled to a digital-to
analog port 30 on the microcontroller, in all cases via electri
cal conduction paths. Such as wires or printed circuit board
conductors. It is preferred that an isolated power supply 23
Supplies all operative power for neurostimulation outputs
such as that to the optical device 16 or the EEG lead stimu
lation inducing circuitry 32. Electrical output from the digi
tal-to-analog port30 is preferably conducted to a transistor 31
that is further coupled to the isolated power supply 23. When
a signal is received at the base of the transistor 31 from the
microcontroller 28, the transistor operates to switch on elec
tricity from the isolated power supply 23 which is further
conducted via electrical coupling to the inductor (stimulation
inducing circuitry) 32. Current flow in the inductor 32
induces a current in the EEG lead, as described in the speci
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Finally, it is preferred that the apparatus operate on a 12
Volt power Supply. It is more preferred that the apparatus
operate on a 6 volt power supply. It is most preferred that the
apparatus operate on a power Supply equivalent to the lowest
power Supply requirement of the components used.
With reference to FIGS. 5-7, a form of electrical signal for
stimulating tissues is disclosed wherein an electrical signal of
relatively high frequency (FIG. 1) is amplitude modulated by
an electrical signal of relatively low frequency (FIG. 6), com
bining to form an electrical signal of the general form shown
in FIG. 7. As discussed above, using pulse width modulation
for the purpose of varying the duty cycle of the electrical
signal of relatively high frequency, the time-averaged current
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deliverable by that signal can be controlled Hence, FIG. 7
shows an example of one embodiment of an amplitude modu
lated pulse width modulated (AMPWM) signal in which the
signal of relatively low frequency shown in FIG. 6 and the
signal of relatively high frequency shown in FIG. 5 form an
AMPWM signal shaped similar to a square wave pulse train.
However, an AMPWM signal may combine signals of
shapes other than square waves. For example, FIG. 8 shows a
signal of relatively low frequency that has a general sinusoi
dal form. When used to amplitude modulate a signal of rela
tively high frequency, as shown in the example of FIG. 1, a
resulting AMPWM signal equivalent is that shown in FIG.9.
An AMPWM signal may also be created from multiple
relatively low frequency components. A signal with multiple
frequency components can be created using methods such as
inverse Fourier Transform theory. FIG. 10 shows an example
of a composite sinusoidal signal with three relatively low
frequency components that are created using an inverse Fou
rier Transform. Such relatively low frequency components
may be selected to provide therapeutic electrical stimulation.
One anticipated benefit of creating Such a composite signal is
to provide for therapeutic electrical stimulation that has mul
tiple frequency-dependent beneficial effects on the tissues to
which it is applied. When a composite signal Such as that
illustrated in FIG.10 is used to amplitude modulate a signal of
relatively high frequency, as shown in the example of FIG. 1,
a resulting AMPWM signal equivalent is that shown in FIG.
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Various apparatus and circuits for creating and using an
electrical signal for stimulating tissues such as an AMPWM
signal are disclosed above. Here, an improved apparatus is
provided, which provides for the generation of electrical tis
sue stimulation signals, such as AMPWM signals, that reduce
tissue impedance and increase depth of signal penetration. A
first embodiment of a tissue stimulation apparatus for provid
ing an electrical tissue stimulation signal that reduces tissue
impedance and increases depth of signal penetration is shown
in FIG. 12, as comprising an electrical stimulation device 101
and an external computing device 102 is provided. Power for
the electrical stimulation device 101 may be provided by an
external power source 105. Such as a line connection or an
adapter for providing a conditioned electrical source, electri
cally coupled to the electrical stimulation device 101 through
a power connector 111.
Internally, the electrical stimulation device 101 may
include a battery charger and switching circuit 107 electri
cally coupled to the power connector 111, enabling the
receipt of electricity from the external power source 105. A
battery 108 may also be electrically coupled to the battery
charger and switching circuit 107. The battery 108 may fur
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ther be connected to other circuits of the electrical stimulation

apparatus through the battery charger and Switching circuit
107 and used to provide electrical power to the other circuits
at times when isolation from line current is required or advan
tageous for operation of the apparatus, such as in times when
the apparatus is being used to provide electrical stimulation to
a Subject. In practice, electrical isolation may be accom
plished through a Switching portion of the battery charger and
switching circuit 107, which may be further electrically
coupled to a controller or processor 103 configured to control
various functions of the electrical stimulation device 101 such

as electrical signal generation and as is further described
herein. Programmed firmware, associated with processor
technologies, for example, may provide for electrical signals
to be sent from the processor 103 to control the switching
portion of the battery charger and switching circuit 107 and to
electrically decouple the electrical stimulation device 101

55

60

18
from the external power source 105 when isolation is required
or desirable. At times when isolation is not required or desir
able, such components as the processor 103, external power
source 105 and battery charger, and switching circuit 107 may
be used to recharge the battery 108 in preparation for subse
quent use. In other words, the processor 103 may be config
ured to command the Switching portion of the battery charger
and switching circuit 107 to couple the external power source
105 to the battery 108 when isolation of the electrical stimu
lation device 101 is not required or desirable and to decouple
the external power source 105 from the battery 108 when
isolation is required or desirable. This coupling may be
accomplished either as a result a signal being sent to a pro
cessor 103 arising from a manual input such as the manual
decoupling of an external power source 105 from line power,
or automatically arising from a software signal being sent to
a processor 103 whenever an operator utilizes a software
interface for using the apparatus to electrically stimulate a
subject. In other words, the processor 103 may be pro
grammed to automatically decouple external power in
response to an operators use of a software interface to use the
apparatus to electrically stimulate a subject.
The battery 108 or other power source may subsequently
energize a power regulation circuit 109 that further provides
conditioned power to other circuits of the electrical stimula
tion device 101 and a common reference ground that may be
used by all circuits. A ground connector 112 may be used to
provide electrical coupling to external circuits, such as those
described herein, for common grounding purposes.
As is also shown in the embodiment of FIG. 13, condi

tioned power from the power regulation circuit 109 may
further be used to energize the processor 103, whereupon a
circuit for creating or generating an electrical signal for
stimulating tissues is realized. This stimulation signal gen
eration circuit may comprise the processor 103, a digital-to
analog (D/A) converter 104, a signal conditioning and ampli
fication circuit 106, a stimulation switching circuit 110, and a
first ground switching circuit 119. Further, the tissue stimu
lation apparatus may include an external computing device
102 coupled to the processor 103 through any suitable com
puter data cable 118 or similar interface, such as a wireless
interface. The external computing device 102 may provide
and be used as a user interface via Software, and may provide
for communication between a user and the processor 103.
Such communication comprising the flow of any and all forms
of data and control signals to set and modify operational
parameters of the electrical stimulation device 101. In other
words, the external computing device is programmed to
exchange data and control signals with the processor and to
allow a user to modify operational parameters of the electrical
stimulation apparatus.
The present invention may be implemented using hard
ware, software or a combination thereof and may be imple
mented in one or more computer systems or other processing
systems. In one embodiment, the invention is directed toward
one or more computer systems capable of carrying out the
functionality described herein. An example of Such a com
puter system is shown at 200 in FIG. 67.
The computer system 200 includes at least one processor
204 that is connected to a communication infrastructure 206

(e.g., a communications bus, cross-over bar, or network). Any
suitable software embodiments may be used with this exem
plary computer system, and the invention may be imple
mented using any Suitable computer system and/or architec
65 tures.

The computer system 200 may include a display interface
202 that forwards graphics, text, and other data from the
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communication infrastructure 206 or from a frame buffer (not
shown) for display on a display unit 230. The computer sys
tem 200 may also include a main memory 208, preferably
random access memory (RAM), and may also include a sec
ondary memory 210. The secondary memory 210 may
include, for example, a hard disk drive 212 and/or a remov
able storage drive 214 Such as a floppy disk drive, a magnetic
tape drive, oran optical disk drive, etc. The removable storage
drive 214 may be configured to read from and/or writes to a
removable storage unit 218 in a well-known manner. The
removable storage unit 218 may include a floppy disk, mag
netic tape, optical disk, etc., which may be read by and written
to the removable storage drive 214. The removable storage
unit 218 may include a computer usable storage medium
having stored therein computer software and/or data.
In alternative embodiments, the secondary memory 210
may include other similar devices for allowing computer
programs or other instructions to be loaded into computer
system 200. Such devices may include, for example, a remov
able storage unit 222 and an interface 220. Examples of such
may include a program cartridge and cartridge interface (Such
as that found in video game devices), a removable memory
chip (such as an erasable programmable read only memory
(EPROM), or programmable read only memory (PROM))
and associated Socket, and other removable storage units 222
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be used with the electrical stimulation device 101.
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ferred via communications interface 224 are in the form of

signals 228, which may be electronic, electromagnetic, opti
cal or other signals capable of being received by communi
cations interface 224. These signals 228 are provided to com
munications interface 224 via a communications path (e.g.,
channel) 226. This path 226 carries signals 228 and may be
implemented using wire or cable, fiber optics, a telephone
line, a cellular link, a radio frequency (RF) link and/or other
communications channels. In this document, the terms "com
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puter program medium' and "computer usable medium' are
used to refer generally to media Such as a removable storage
drive 214, a hard disk installed in hard disk drive 212, and

signals 228. These computer program products provide Soft
ware to the computer system 200. The invention may include
Such computer program products.
Computer programs (also referred to as computer control
logic) are stored in main memory 208 and/or secondary
memory 210. Computer programs may also be received via
communications interface 224. Such computer programs,
when executed, enable the computer system 200 to perform
according to the features of the present invention, as dis
cussed herein. The computer programs, when executed,
enable the processor 204 to perform according to the features
of the present invention. Accordingly, such computer pro
grams serve as controllers of the computer system 200.
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Upon establishment of signal parameters in a processor
103, along with establishment of other operational param
eters, such as the aforementioned decoupling of an external
power source 105, signals are sent from the processor 103 to
a D/A converter 104, whereupon an analog Voltage represent
ing an electrical signal for stimulating tissues is first achieved.
The analog voltage is further provided to an electrically
coupled signal conditioning and amplification circuit 106.
where a substantially equivalent signal is created with advan
tageous enhancements such as, but not limited to, increased
Voltage amplitude, decreased signal-to-noise ratio, and
increased current capability.
In some embodiments, provisions may be made to the
electrical stimulation apparatus for the selective control of the
delivery of an electrical signal for stimulating tissues to a
plurality of stimulation connectors 113. A stimulation switch
ing circuit 110 is electrically coupled to the processor 103.
whereupon control signals from the processor 103 allow for
the signal from the signal conditioning and amplification
circuit 106 to be advantageously switched to any number of
independent electrical conductors or conduction paths. Fur
ther, the independent electrical conductors or conduction
paths are electrically coupled with a first ground Switching
circuit 119, the first ground switching circuit 119 being fur
ther electrically coupled to the processor 103. Control signals
from the processor 103 allow for selective switching of the
independent conductors to an apparatus ground point, pro
viding advantageous control of the independent conductors
use as either a conduction path for an electrical signal for
stimulating tissues or a ground. Further electrical conduction
paths are provided for each independent conductor passing
through a first ground switching circuit 119, with each inde
pendent conductor terminating at one of a plurality of stimu
lation connectors 113.
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The apparatus may include a number of electrical conduc
tors that provide electrical coupling between a number of
connectors and input/output (I/O) ports of a processor 103 in
the electrical stimulation device 101 for the embodiments

In an embodiment where the invention includes the use of

Software, the Software may be stored in a computer program
product and loaded into computer system 200 using the
removable storage drive 214, the hard drive 212, or the com
munications interface 224. The control logic (software),
when executed by the processor 204, causes the processor

similar interface. Such as a wireless interface. In other words,

the external computing device 102 is configured to establish
parameters of the electrical signals generated by the electrical
stimulation device 101. Such signal parameters include, but
are not limited to waveform, frequency components, phase,
pulse width, duty cycle, and amplitude components such as
minimum amplitude, maximum amplitude, and offset Volt
age. Various methods of establishing signal parameters may

and interfaces 220, which allow software and data to be

transferred from the removable storage unit 222 to the com
puter system 200.
The computer system 200 may also include a communica
tions interface 224. The communications interface 224 may
be configured to allow software and data to be transferred
between the computer system 200 and external devices. The
communications interface 224 may include a modem, a net
work interface (such as an Ethernet card), a communications
port, a Personal Computer Memory Card International Asso
ciation (PCMCIA) slot and card, etc. Software and data trans
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204 to perform according to the functions of the invention as
described herein. In another embodiment, the invention may
be implemented primarily in hardware using, for example,
hardware components, such as application specific integrated
circuits (ASICs). Implementation of the hardware state
machine so as to perform the functions described herein will
be apparent to persons skilled in the relevant art(s).
In yet another embodiment, the invention may be imple
mented using a combination of both hardware and software.
In Some embodiments, and as shown in FIG. 12, generating
an electrical signal for stimulating tissues begins with signal
parameters being established through various software meth
ods used in an external computing device 102 and communi
cated to a processor 103 via any suitable data cable 118 or
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shown. Specifically, an auxiliary power Supply connector 114
may be provided. The apparatus may include a Switch com
prising an electrical conductor first connected to an auxiliary
power Supply connector 114 then to a Switch, then via another
electrical conductor to an auxiliary I/O connector 116. The
Switch may be used for various purposes to indicate an event
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to the processor 103. One exemplary purpose is the use of the
Switch by a Subject receiving electrical stimulation to marka
point in time of any particular interest.
The electrical stimulation device 101 may also include a
plurality of conductors or control I/O connectors 115 that
provide electrical coupling to I/O ports of the processor 103.
Specifically, the control I/O connectors 115 may provide
control signals between the processor 103 and various elec
trical apparatus or peripheral devices coupled to the electrical
stimulation device 101, examples of which are described
further herein. The apparatus may further include a number of
lead test ports 117 electrically coupled to the processor 103
for electrically coupling electrical conductors or other cou
plings, to the processor 103 for the purpose of testing the
electrical conducting integrity of any combination of Such
electrical conductors, or other couplings, such as wires com

22
upon processor firmware, for example, makes a comparison
between the electrical signal of known properties and the
signal conducted through a lead being tested in order to deter
mine the electrical conducting integrity of the lead.
As shown in FIG. 14, a second embodiment of tissue stimu
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bined with sensors, such as surface electrodes, henceforth

referred to as “leads”, used to conduct electrical energy
between tissues and the electrical stimulation device 101.

As is also shown in FIG. 13, the electrical stimulation

device 101 may include one or more ground leads 120, a
plurality of stimulation leads 121, and provision at a termi
nating end of all leads for an electrode 122 adapted to be
placed on tissues in either an invasive or non-invasive way.
The apparatus also has provision for one or more external
stimulation devices, such as an optical device 123, electro
magnetic device 170, electromechanical device 171 or an
audio device 172, electrically coupled by one or more exter

25

device 101.

In an exemplary operation, the apparatus of FIG. 14 pro

nal stimulation device cables 124. As shown in FIG. 13 the

external stimulation devices may include an optical device
123 comprising eyeglasses adapted with illuminating or simi
lar photic devices, such as light emitting diodes, or with
displays for showing digital images to a subject undergoing
therapy. The external stimulation devices may include an
audio device 172 adapted to play music during therapeutic
activity.
In operation, the apparatus of FIG. 13 provides stimulation
from the electrical stimulation device 101 to tissues disposed
between stimulation leads 121 and ground leads 120 such that
an approximate vector path of electrical current flow extends
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between electrodes 122 associated with the stimulation leads

121 and electrodes 122 associated with the ground leads 120.
The processor 103 may be programmed to provide control
signals that selectively control the stimulation Switching cir
cuit 110 and the first ground switching circuit 119 to cause the
leads 121 to serve as either stimulation leads delivering
stimulation or as ground leads serving as ground sources in
Such a way as to create multiple spatial paths of electrical
stimulation through tissues.
In addition, as shown in FIG. 13, stimulation may be pro
vided by an external stimulation device 123 operatively
coupled to a stimulation connector 113 that is being used as an
active stimulation electricity source through control of a
stimulation Switching circuit 110 by signals from a processor
103.

In addition, in the apparatus shown in FIG. 13, electrical
conducting integrity of any stimulation lead 121, any ground
lead 20, or any external stimulation device 123 may be tested
by effecting physical contact between a lead, preferably by
providing mechanical connection between a leads conduc
tion interface such as an electrode 122 and a lead test port 117.
In testing for electrical conducting integrity, a processor 103
may be selectively used to output an electrical signal of
known properties to a lead 121 being tested, whereupon the
electrical signal conducted by the lead being tested can be
acquired by the processor 103 through a lead test port 117.
Any number of Suitable analyses may be conducted, where

lation apparatus for providing an electrical tissue stimulation
signal that reduces tissue impedance and increases depth of
signal penetration is shown as comprising an electrical stimu
lation device 101 and a biopotential acquisition device that
measures biopotential Voltage in tissue to be stimulated. The
biopotential acquisition device may include a biopotential
amplifier module 127 comprising a biopotential amplifier
130, an impedance testing circuit 131, a second ground
switching circuit 129 and a series of inductors 128 operatively
coupled to conductors extending from the second ground
Switching circuit 129 and terminating at biopotential acqui
sition lead connectors 126 and thus operatively coupled to
biopotential acquisition leads 125 coupled to the connectors
126. Further provisions may be made for any number of
biopotential acquisition leads 125, and any number of ground
leads 120, each lead 125, 120 including a sensor such as a
surface electrode 122 adapted to be placed on tissues. Further
provisions may be made for electrical coupling of a biopo
tential amplifier module 127 to the electrical stimulation
device 101 through stimulation lead connectors 113, a auxil
iary power supply connector 114, control I/O connectors 115,
and auxiliary I/O connectors 16 of the electrical stimulation
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vides stimulation from the electrical stimulation device 101 to

tissues, whereupon a biopotential Voltage is measured by the
biopotential amplifier 130 operatively coupled to any number
of biopotential acquisition leads 125 and any number of
ground leads 120 having electrodes 122 adapted to be placed
on tissues, the biopotential Voltage including, but not being
limited to, electroencephalographic (EEG) Voltage, elec
tromyographic (EMG) Voltage, and electrocardiographic
Voltage.
In the apparatus of FIG. 14, an electrical signal for stimu
lating tissues may be induced using the inductors 128 dis
posed adjacent the independent conductors extending from
the second ground Switching circuit 129 and terminating at
biopotential acquisition lead connectors 126, the electrical
signal being provided by the electrical stimulation device
101, and the inductors 128 being electrically coupled to the
electrical stimulation device 101 at stimulation connectors
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113, whereupon selective control of the electrical signal for
stimulating tissues is accomplished as previously disclosed
herein. In other words, the biopotential acquisition device
includes one or more inductors 128 electrically coupled to the
electrical stimulation device 101 and operatively coupleable
one or more respective biopotential acquisition leads 125, the
electrical stimulation device and inductors being configured
to selectively deliver tissue stimulation signals through the
one or more biopotential acquisition leads of the biopotential
acquisition device.
In the apparatus of FIG. 14, data transfer of acquired bio
potential voltage may be provided between the processor 103
and the biopotential amplifier 130 through any I/O port, such
as a control I/O connector 15 or an auxiliary I/O connector
116. In certain embodiments, the biopotential voltage data
may be used at any time to determine or alter parametric
values of an electrical signal for stimulating tissues, such as
via analysis using Software in an external computing device
102 with subsequent control data being sent from the external
computing device 102 to a processor 103 in an electrical
stimulation device 101. In other words, the external comput
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ing device 102 is configured to determine parametric value of
an electrical tissue stimulation signal in response to biopo
tential Voltage data obtained by the biopotential acquisition
device and to send corresponding control data to the proces
Sor 103.

In the apparatus of FIG. 14, the processor 103, for example,
of the electrical stimulation device 101 may selectively
sample biopotential Voltage data from the biopotential ampli
fier 130 of the biopotential acquisition device at times of
minimal electrical stimulation signal amplitude, preferably
Zero amplitude, within the period of a high frequency signal
component of an AMPWM signal. Thus, the biopotential
acquisition leads 125 may be used for the dual purpose of both
acquiring biopotential Voltage and delivering an electrical
signal for stimulating tissues at overlapping, or simultaneous,
times. The frequencies of a high frequency signal component
of an AMPWM signal may be selected to be multiples of
integral powers of two, including but not limited to integral
multiples of 256 (i.e. 28) such as for example 14,336 hertz
(256x56) and 16,384 hertz (256x64). Such selection of fre
quencies facilitates mathematical analysis of acquired biopo
tential Voltage data. Such mathematical analysis may include
a FourierTransform analysis whereupon a number of samples
per second equal to an integral power of two may be pre
ferred. In the examples of AMPWM signal high frequency
component frequencies of 14.336 hertz and 16,384 hertz
given, sampling rates for biopotential Voltage data of 2,048,
1,024, 512, 256 and 128 samples per second are readily
achieved within equally spaced intervals of minimal electri
cal stimulation signal amplitude in the AMPWM signal.
In the apparatus of FIG. 14, the second ground Switching
circuit 129 may be operatively coupled to the electrical stimu
lation device 101 using a control I/O connector 15. Opera
tionally, the second ground switching circuit 129 receives
control signals from the processor 103, which allows for
selective switching of any biopotential acquisition lead 125 to
an apparatus ground point, permitting advantageous control
of the biopotential acquisition leads 125 use as either a
conduction path for an electrical signal for Stimulating tis
Sues, a conduction path for a biopotential Voltage to the bio
potential amplifier 130, or a ground. Among other things,
such selective switching of a biopotential acquisition lead 125
permits selective use as a reference lead to the biopotential
amplifier 130 or as a differential lead to the biopotential
amplifier 130, facilitating differential comparison of biopo
tential Voltages at more than one acquisition site on a tissue.
In the apparatus of FIG. 14, an impedance testing circuit
131 may be included in the biopotential acquisition device
and operationally coupled to the biopotential amplifier 130.
The impedance testing circuit 131 may also be coupled to the
electrical stimulation device 101 using auxiliary I/O connec
tors 16. In such use, the impedance testing circuit 131 may be
used to monitor the impedance of tissues in mechanical con
tact with biopotential acquisition leads 125 and a ground lead
20, each comprising an electrode 122 adapted to be placed on
the tissues. Data representing the impedance of tissues is
transferred to the processor 103 of the electrical stimulation
device 101 via electrical coupling, for example. The data
representing impedance of tissues may be used to determine
or alter parametric values of an electrical signal for stimulat
ing tissues through, for example, analysis using software in
the external computing device 102, with subsequent control
data being sent from the external computing device 102 to the
processor 103 in the electrical stimulation device 101.
The data representing impedance of tissues and ongoing
monitoring for biopotential Voltage integrity, Such as, but not
limited to, EEG measurement integrity, may be used to deter
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mine or alter parametric values of an electrical signal for
stimulating tissues, such as an AMPWM signal.
The use of methods to monitor for biopotential voltage
integrity accomplishes various means of guiding a user and
assuring improved biopotential signal data throughout an
acquisition time period. For example, the apparatus may
include an alert for notifying a user if integrity is lost during
treatment. Such alert may be provided, for example, via soft
ware analysis in an external computing device 102. In another
embodiment, such alert may be sent to a remote indicator
Such as a pager worn by a user. Further, the apparatus may
include various means of indicating to a user when good
biopotential Voltage integrity is achieved as biopotential
acquisition leads 125 and ground leads 120 are first being
applied to tissues, prior to the acquisition of data. Such indi
cators may be provided, for example, via graphic user inter
face Software in an external computing device 102 or via any
number of hardware indication means.

With reference to FIG. 15, another embodiment of a tissue
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stimulation apparatus for providing an electrical tissue stimu
lation signal that reduces tissue impedance and increases
depth of signal penetration is shown as comprising an elec
trical stimulation device 101 and an adjunct electrical stimu
lation apparatus 132 to be used with an independent biopo
tential Voltage measurement apparatus, Such as, but not
limited to, an EEG measurement apparatus 137. Under nor
mal operating conditions, an EEG measurement apparatus
137 is typically used only for the purposes of acquiring EEG
Voltage data and for providing Such data to an external com
puting device 102 through any data cable 138 or other cou
pling capable of sufficiently transferring the data. Acquisition
of the EEG voltage is normally accomplished through any
number of leads electrically coupled to an EEG measurement
apparatus 137 at an interface 139, for example. Such number
of leads may include an EEG sensor set 136 comprising, but
not being limited to, a series of conductors, a series of elec
trodes and features for positioning the electrodes, such as via
integration of Such sensors in a cap adapted to be worn by a
Subject. In other words, the tissue stimulation apparatus may
comprise a sensor set 136, an independent biopotential Volt
age measurement apparatus 137, and an adjunct electrical
stimulation apparatus 132 operatively connected between the
sensor set 136 and the independent biopotential voltage mea
Surement apparatus. The independent biopotential Voltage
measurement apparatus 137 may be operatively coupled to
the electrical stimulation device 101, and may be configured
to transmit through stimulation connectors 113 to the sensor
set, electrical tissue stimulation signals received from the
electrical stimulation device 101, to transmit biopotential
voltage from the sensor set 136 to the independent biopoten
tial Voltage measurement apparatus 137, and to receive con
trol signals from the processor 103 of the electrical stimula
tion device 101 through control I/O connectors 115,
The exemplary apparatus illustrated in FIG. 15 enables use
of an independent biopotential Voltage measurement appara
tus. Such as, but not limited to, an EEG measurement appa
ratus 137, within an apparatus for providing an electrical
signal for stimulating tissues. This use may be accomplished
by placing an adjunct electrical stimulation apparatus 132
operatively between an EEG sensor set 136 and an EEG
measurement apparatus 137. The adjunct electrical stimula
tion apparatus 132 may include an adjunct Switching control
135 operatively coupled to a processor 103 of an electrical
stimulation device 101 using control I/O connectors 115. The
adjunct electrical stimulation apparatus may also include a
series of EEG lead conductors 142 and matched transfer

conductors 140, for example, along with a series of adjunct
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switching circuits 133 operatively coupled to the adjunct
switching control 135 via switching control conductors 141,
and further operatively coupled to stimulation connectors 113
of the electrical stimulation device 101.

In operation, the apparatus of FIG. 15 provides for an
adjunct electrical stimulation apparatus 132 operatively
coupled to an electrical stimulation device 101 to both receive
electrical signals through stimulation connectors 113 for
stimulating tissues and to transfer control signals to a proces
sor 103 through control I/O connectors 115. The adjunct
electrical stimulation apparatus 132 may be further opera
tively coupled to an EEG sensor set 136 at a cable interface
connector 134 for receiving EEG voltage. The adjunct elec
trical stimulation apparatus 132 may be further operatively
coupled to an EEG measurement apparatus 137 at an interface
139 such as the same connecting features provided by an EEG
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sensor set 136.

With reference to FIGS. 15 and 16, a series of adjunct
Switching circuits 133 may be provided, each comprising any
substantial circuit for switching 143, for example, that pro
vides a selectable conduction pathway for an EEG lead con
ductor 142 between (a) an electrical signal for stimulating
tissues, such as provided by an electrical stimulation device
101 through electrical coupling at stimulation connectors
113, (b) a transfer conductor 140 terminated at an interface
139 and further provided to an independent EEG measure
ment apparatus 137, or (c) a ground. Further provision made
in the adjunct Switching circuit 133 may include Switching
control conductors 141 electrically coupled to an adjunct
switching circuit 135, which may be used, for example, to
determine the state of the adjunct switching circuit 133 and
therefore the conduction path provided to the EEG lead con
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ductor 142.

As shown in FIG. 15, the electrical stimulation device 101

may be combined with an adjunct electrical stimulation appa
ratus 132 and biopotential Voltage measurement apparatus,
such as an EEG measurement apparatus 137. At times, for
example, when a biopotential Voltage measurement is
required, biopotential voltage from a particular EEG lead
conductor 142 may be directed to a transfer conductor 140 by
selective Switching via an adjunct Switching control 135 oper
ated by the processor 103 in the electrical stimulation device
101. Alternately, at times, such as when an electrical signal
for stimulating tissues is required, the signal may be directed
from a stimulation connector 113 to a particular EEG lead
conductor 142 by selective Switching from an adjunct Switch
ing control 135 operated by the processor 103 in the electrical
stimulation device 101. Alternately, at times, such as when a
particular EEG lead conductor 142 is to be grounded, selec
tive switching from an adjunct switching control 135 oper
ated by the processor 103 in the electrical stimulation device
101 may be used to electrically couple the EEG lead conduc
tor 142 to ground. In other words, the processor 103 of the
electrical stimulation device 101 and the adjunct switching
control may direct biopotential Voltage from selected elec
trodes of the sensor set 136 to the biopotential measurement
apparatus 137 by selective switching via the adjunct switch
ing control 135 operated by the processor 103 when a biopo
tential Voltage measurement is required, may direct tissue
stimulation signals from the electrical stimulation device101
through selected Stimulation connectors 113 to correspond
ing electrodes of the sensor set 136 through respective EEG
lead conductors 142 by selective switching via the adjunct
switching control 135 operated by the processor 103 when
tissue stimulation is required, and may couple selected elec
trodes of the sensor set 136 to ground by selective switching
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via the adjunct switching control 135 operated by the proces
sor 103 when grounding of an electrode is required.
As shown in FIG. 14, inductors 128 and a second ground
switching circuit 129 of the apparatus of FIG. 14 may be
replaced, for example, by an adjunct Switching circuit 133
and an adjunct switching control 135 to control the use of
individual leads. In other words, the biopotential acquisition
device of FIG. 14 may be modified to include at least one
adjunct Switching circuit 133 and an adjunct Switching con
trol 135 electrically coupled to the electrical stimulation
device 101, with the adjunct switching circuit 133 being
operatively coupled to at least one biopotential acquisition
lead 125, the electrical stimulation device 101 and an adjunct
switching control 135 selectively connecting the electrical
stimulation device 101 to selected leads to transmit tissue

stimulation signals to the selected leads and connecting
selected leads to the biopotential amplifier 130 to transmit
biopotential voltages to the biopotential amplifier 130.
Accordingly, as shown in FIG. 17, the tissue stimulation
apparatus may comprise an electrical stimulation device 101
and a biopotential amplifier and switching module 155, and
the module may further comprise a biopotential amplifier
130, an impedance testing circuit 131, a series of EEG lead
conductors 142 operatively coupled to conductors terminat
ing at biopotential acquisition lead connectors 126, matched
transfer conductors 140, a series of adjunct Switching circuits
133 operatively coupled to the adjunct switching control 135
via switching control conductors 141, and further operatively
coupled to stimulation connectors 113 of an electrical stimu
lation device 101. Further provisions may be made for any
number of biopotential acquisition leads 125, and any number
of ground leads 120, and a mechanism that may be used with
the leads to provide for electrodes 122 adapted to be placed on
tissues. Further provisions may be made for electrical cou
pling of a biopotential amplifier and switching module 155 to
the electrical stimulation device 101 through stimulation con
nectors 113, auxiliary power supply 14, control I/O connec
tors 115 and auxiliary I/O connectors 16.
In an exemplary operation, the apparatus of FIG. 17 pro
vides stimulation from the electrical stimulation device 101 to

tissues, whereupon a biopotential Voltage may be measured
by a biopotential amplifier 130 operatively coupled through
an adjunct switching circuit 133, transfer conductor 140 and
EEG lead conductor 142 to any number of biopotential acqui
sition leads 125, any number of ground leads 120 and the
electrode 122 adapted to be placed on tissues. The biopoten
tial Voltage may include, but is not limited to including,
electroencephalographic (EEG) Voltage, electromyographic
(EMG) Voltage, and/or electrocardiographic Voltage.
As shown in FIG. 17, an electrical signal for stimulating
tissues may be electrically coupled to any number of biopo
tential acquisition leads 125, any number of ground leads 120
and the electrode 122 adapted to be placed on tissues, the
electrical signal being provided by the electrical stimulation
device 101, through an adjunct switching circuit 133, transfer
conductor 140 and EEG lead conductor 142, where the

adjunct Switching circuit 133 is operatively coupled to an
adjunct Switching control 135 via Switching control conduc
tors 141, and further operatively coupled to stimulation con
60
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nectors 113 of the electrical stimulation device 101, where

upon selective control of the electrical signal for stimulating
tissues may be accomplished as previously disclosed herein.
Further, and with particular reference to FIG. 18, the
adjunct Switching circuit 133 and an adjunct Switching con
trol 135 of the apparatus of FIG. 15 may be replaced by
inductors 128 and a second ground Switching circuit 129, as
taught in FIG. 14 to control the use of individual leads. In
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other words, the adjunct electrical stimulation apparatus 132
may be modified to include a ground switching circuit 129
operatively coupled to the processor 103 of the electrical
stimulation device 101, to the biopotential amplifier 130, and
by conduction paths to respective electrodes of the sensorset,
a plurality of inductors 128 operatively coupled to the elec
trical stimulation device 101 and to the conduction paths, and
the processor and ground Switching circuit may be configured
to provide selectable conduction pathways for tissue stimu
lation signals between the electrical stimulation device 101
and the electrodes of the sensor set, and for biopotential
voltages between the electrodes of the sensor set and the
biopotential Voltage measurement apparatus 137.
Accordingly, as shown in FIG. 18, as the tissue stimulation
apparatus may comprise a basic electrical stimulation appa
ratus 1 and an adjunct electrical induction and Switching
apparatus 156 to be used with an independent biopotential
Voltage measurement apparatus, such as, but not limited to, an
EEG measurement apparatus 137. Under normal operating
conditions, an EEG measurement apparatus 137 is typically
utilized only for the purposes of acquiring EEG voltage data
and for providing Such data to an external computing device
102 through any data cable 138 or other coupling capable of
sufficiently transferring the data. Acquisition of the EEG
Voltage may be accomplished through any number of leads
electrically coupled to an EEG measurement apparatus 137 at
an interface 139, for example. Such number of leads may
include an EEG sensor set 136 comprising, but not being
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interface connector 134 for receiving EEG voltage. The
adjunct electrical stimulation apparatus 132 may further be
operatively coupled to an EEG measurement apparatus 137 at
an interface 139 Such as the same connecting features pro
vided by an EEG sensor set 136.
With reference to FIG. 19, another embodiment of a tissue
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limited to, a series of conductors, a series of electrodes and

features for positioning the electrodes, such as a cap adapted
to be worn by a user and into which the electrodes may be
integrated.
The exemplary apparatus illustrated in FIG. 18 enables use
of an independent biopotential Voltage measurement appara
tus. Such as, but not limited to, an EEG measurement appa
ratus 137, within the tissue stimulation apparatus. This use
may be accomplished by placing an adjunct electrical induc
tion and Switching apparatus 156 operatively between an
EEG sensorset 136 and an EEG measurement apparatus 137,
whereupon said adjunct electrical induction and Switching
apparatus 156 comprises a second ground Switching circuit
129 operatively coupled to any number of transfer conductors
140 and EEG lead conductors 142. In the system of FIG. 18,
a second ground Switching circuit 129 may be further opera
tively coupled to an electrical stimulation device 101 using a
control I/O connector 15. Operationally, the second ground
Switching circuit 129 receives control signals from a proces
sor 103, which allows for selective switching of any EEG lead
conductor 142 to a system ground point, permitting advanta
geous control of the EEG lead conductor's 142 use as either a
conduction path for an electrical signal for Stimulating tis
Sues, or a conduction path for an EEG measurementapparatus
137, or a ground. Further provisions may be made for elec
trical coupling of an adjunct electrical induction and Switch
ing apparatus 156 to a basic electrical stimulation apparatus 1
through stimulation connectors 113, auxiliary power Supply
14, control I/O connectors 115 and auxiliary I/O connectors
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16.

In operation, the apparatus of FIG. 18 provides for an
adjunct electrical induction and Switching apparatus 156
operatively coupled to the electrical stimulation device 101 to
both receive electrical signals through stimulation connectors
113 for stimulating tissues and to transfer control signals
between a processor 103 and a second ground Switching
circuit 129 through control I/O connectors 115. The adjunct
electrical induction and switching apparatus 156 may further
be operatively coupled to an EEG sensor set 136 at a cable
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stimulation apparatus 144 for providing an electrical signal
for stimulating tissues comprises an electrical stimulation
device 101, may comprise an external computing device 102.
and comprises one or more circuits adapted to provide elec
trical stimulation signals from the electrical stimulation
device to tissues of a Subject in accordance with features and
operations of the embodiments, or Substantial equivalents,
such as are illustrated in FIGS. 12-18 and taught herein. With
further reference to FIG. 19, the tissue stimulation apparatus
144 for providing an electrical signal for stimulating tissues
may include a mobile apparatus 146 Such as a wheeled cart or
a wheeled Stand for transportability, and a material Supplies
storage and use apparatus 147 that carries consumable Sup
plies for use in administering tissue stimulation signals to a
Subject.
In operation, the tissue stimulation apparatus 144 of FIG.
19 provides a mobile system for providing an electrical signal
for stimulating tissues, wherein the mobile apparatus 146
facilitates movement of the tissue stimulation apparatus 144
to a subject, and wherein a tissue stimulation apparatus 144
may provide stimulation through composite stimulation leads
145. Such composite stimulation leads 145 comprising any
combination of stimulation leads 121, ground leads 120, and/
or external stimulation device cables 124.

In the tissue stimulation apparatus 144 shown in FIG. 19, a
number of consumable supplies may be used with the tissue
stimulation apparatus to provide an electrical signal for
stimulating tissues, the Supplies including, but not being lim
ited to conductive pastes, conductive gels, cleaning materials,
Such as cotton or gauze, cleaning agents, such as rubbing
alcohol, and/or any number of Supporting materials. In the
tissue stimulation apparatus 144 of FIG. 19, the material
Supplies storage and use apparatus 147 may be operatively
coupled to or carried by the mobile apparatus 146, for
example, to enable presenting the consumable Supplies dur
ing use and storing the consumable Supplies during non-use.
Specifically, the material Supplies storage and use apparatus
147 may comprise, for example, a plurality of receptacles and
storage features, including, but not limited to, a waste storage
receptacle 148, a conductive gel receptacle 149, a conductive
paste receptacle 150, a cleaning materials receptacle 151, an
alcohol receptacle 152, any number of other Supporting mate
rials receptacles 153, and/or an electrode storage receptacle
154.

In the tissue stimulation apparatus 144 shown in FIG. 19.
provisions may be made for any method of sensing the quan
tities of materials stored in receptacles such as, but not limited
to, the waste storage receptacle 148, the conductive gel recep
tacle 149, the conductive paste receptacle 150, the cleaning
materials receptacle 151, the alcohol receptacle 152, and/or
any further number of supporting materials receptacles 153.
The method is further realized using any Suitable computing
device 102 integral to operate with the composite electrical
stimulation apparatus 144 to acquire signals from sensors 60
using software to manage inventory. In other words, the tissue
stimulation apparatus 144 may include one or more sensors
60 carried by the material supplies and use apparatus 147 and
configured to sense the quantities of materials stored in recep
tacles of the material Supplies storage and use apparatus 147.
The tissue stimulation apparatus 144 may include a comput
ing device 102 coupled to the one or more sensors and con
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figured to manage inventory in response to signals acquired
from the one or more sensors. The method may further
include use of, for example, various alerts when inventory of
any material reaches a predetermined low point. In other
words, the tissue stimulation apparatus 144 may be config
ured to generate an alert when inventory of any material
reaches a predetermined low point. The method may further
include interfacing, such as via Software, to provide orders to
replenish material inventory when a pre-determined low
point is reached. In other words, the tissue stimulation appa
ratus 144 may be configured to order materials necessary to
replenish inventory when a pre-determined low point is
reached. The method may further provide for interfacing with
a network, Such as the Internet 62, and to enable ordering by
a remote Supply entity for the purposes of replenishing mate
rial inventory when a pre-determined low point is reached. In
other words, the tissue stimulation apparatus 144 may be
configured to order materials by interfacing with a commu
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nications network Such as the internet 62.

In the tissue stimulation apparatus 144 shown in FIG. 13,
the electrode storage receptacle 154 may be configured to
provide storage for electrodes 122 for leads, the electrodes
made of for example, photosensitive materials, such as sil
Ver-silver/chloride. In practice, the electrode storage recep

via the Internet.
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tacle 154 allows the electrodes 122 to be covered so as to

block access of ambient light during periods of non-use.
In tissue stimulation apparatus Such as those shown in a
number of the figures, the use of leads may be dynamically
altered between (a) conducting biopotential Voltages, (b) con
ducting an electrical signal for stimulating tissues and (c) a
ground, in conjunction with the use of computational analysis
of the acquired data, Such as biopotential data, providing
indication of a region of tissue to be stimulated. Based on Such
analysis, Sufficient leads may be identified and appropriately
placed so as to provide a number of possible conduction paths
passing in near proximity to the region of tissue of interest.
Then, control signals from a processor 103 of an electrical
stimulation device 101 may be used to selectively switch use
of the leads, in accordance with methods taught herein, to
provide any number of dynamically controlled conductors
and grounds for an electrical signal for stimulating tissues.
The electrical stimulation device 101 may then be used to
deliver the electrical signal to the appropriate region of tissues
and may further be used to assess Subsequently acquired data
for the purpose of Subsequent altering of lead use. In other
words, tissues of a subject may be stimulated by first provid
ing a tissue stimulation apparatus configured to dynamically
alter the use of leads between conducting biopotential volt
ages, conducting an electrical signal for stimulating tissues,
and grounding, in response to a computational analysis of
biopotential data acquired from a region of tissue to be stimu
lated, acquiring biopotential data from a region of tissue to be
stimulated, performing a computational analysis of the
acquired biopotential data, in response to the analysis, iden
tifying and placing Sufficient leads so as to provide a number
of possible conduction paths passing in near proximity to a
region of tissue of interest, and dynamically controlling elec
trical signal delivery to the region of tissue of interest by
selectively switching the use of the leads as conductors and
grounds. In addition Subsequently acquired data may be
assessed for the purpose of Subsequent altering of lead use.
In place of a battery 108 any one of a number of circuit
embodiments known in the art may be used to provide elec
trical isolation from an external power source 105 and may
further be used to provide isolated electrical power to one or
more circuits of the electrical stimulation device 101.
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In embodiments of the present invention, an external com
puting device 102 may functionally interface with other net
work computing devices, including but not limited to com
puting devices coupled to or otherwise accessible via the
Internet. Such interfaces to other network computing devices
may be used, for example, to facilitate the determination or
alteration of parametric values of an electrical signal for
stimulating tissues through analysis using software in a net
work computing device, with Subsequent control data being
sent from the network computing device via the functional
interfaces to an external computing device 102, further opera
tionally coupled to a processor 103 in an electrical stimula
tion device 101. In other words, the external computing
device 102 may be configured to functionally interface with at
least one other network computing device to determine para
metric values of an electrical tissue stimulation signal; and to
receive Subsequent corresponding control data from the other
network computing device via the functional interfaces. The
external computing device 102 may be configured to func
tionally interface with the other network computing device
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In embodiments of the present invention, the time-aver
aged current flow of an electric signal for stimulating tissues
may be varied by modifying the duty cycle of the high fre
quency component of an AMPWM signal. This method of
varying the time-averaged current flow may include varying
stimulation intensity provided to a Subject by an external
stimulation device 123 such as, but not limited to, the light
intensity of an optical stimulation device, the magnetic field
strength of an electromagnetic device, the mechanical action
of an electromechanical stimulation device or the Sound
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intensity of an audio stimulation device.
In embodiments of the present invention, the apparatus for
providing electrical signals for stimulating tissues may be
integrated with other instruments used during periods of
therapy. For example, such instruments may be electrically
coupled to an electrical stimulation device 101 through aux
iliary I/O connectors 16. In other words, the tissue stimulation
apparatus may include data collection instruments configured
to collect data on a Subject during periods of therapy and
electrically coupled to the electrical stimulation device 101.
Among other things, this approach allows simultaneous col
lection of instrument data during periods of therapy.
Embodiments of the present invention may include the use
of a software program to execute various means of identifying
a Subject. Such means may include, but are not limited to,
electronic or magnetic identification media. Such means may
also include, but are not limited to, the use of digital photo
graphs of a subject to both aid in identification of the subject
and to provide visual Support to aid in proper location for the
placement of any leads associated with the apparatus.
Software may also be used to facilitate the playing of music
through an external stimulation device 123 for the subject
during therapy, with the music being chosen, for example, to
enhance therapeutic effect.
Software may also be used to facilitate the playing of
educational audio or video media clips for the Subject at any
time associated with therapy, with the media clips being cho
sen, for example, to enhance therapeutic effect.
A number of methods have been described for deriving
quantities such as the frequency, phase, pulse width duty
cycle, and amplitude of electrical signals for stimulating tis
Sues, e.g., signals such as AMPWM signals, that reduce tissue
impedance and increase depth of signal penetration. Such
derivations are anticipated through either manual means Such
as those performed by a human, or automatic means such as
those performed by computational methods in software, or by
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any combination of both means. In various methods taught
herein, the term “frequency” refers to any singular value or to
any range of values that change over a period of time during
therapeutic activity (e.g. a “frequency Sweep').
Such signals may be used to stimulate brain tissue. Accord
ing to one method of electrically stimulating tissue, paramet
ric values of an electrical tissue stimulation signal are deter
mined in response to biopotential Voltage data obtained from
a region of tissue to be stimulated. An electrical stimulation
signal having the determined parametric values is then gen
erated and applied to the region of tissue. One exemplary way
of determining parametric signal values includes first taking a
measure of the EEG activity of at least a portion of the brain,
or the EEG of the entire brain, of a subject prior to the
generation and application of any electrical signal for the
purposes of stimulating brain tissues. Upon collection of EEG
activity from the brain for a sufficient period of time, the EEG
data is analyzed for any number of relationships. A sufficient
period of time for collecting EEG activity may be between,
for example, one second and one hour. The relationships for
which the EEG data is analyzed may include, but are not
limited to, the amount of measured Voltage in single fre
quency components; in composites of multiple frequencies,
also known as frequency bands; and/or in frequency band
ratios, for the cases of both individual EEG sites and for

multiple EEG sites. These relationships may further include,
but are not limited to, various statistical analyses involving
measured EEG voltages and their frequency and phase com
ponents, taken at both individual EEG sites and for multiple
EEG sites. These statistical analyses may include, but are not
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embodiment of the invention, the EEG of the brain can be
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limited to, measures of variance, correlation, and/or coher

ence. These relationships may further include, but are not
limited to, various analyses that provide indication of the
spatial origin and/or source localization of the measured
EEG, such as that accomplished by performing “inverse
EEG' analysis.
Parametric determination may further rely on making com
parisons between the findings of the EEG analysis and similar
measures known to represent normal brain activity in a
healthy normal population of living beings such as human
beings. Such a comparison may be performed, for example,
for the purpose of quantifying differences between the mea
sured EEG of a subject and the EEG expected in normal brain
activity. Such differences are used to identify particular brain
sites or regions where frequency and amplitude components
of the subject's EEG are either excessive; that is, where they
exhibit greater values than normal; diminished; that is, where
they exhibit values lower than normal; or highly variable; that
is, where they exhibit values that fluctuate more than normal.
As shown in FIG. 22, parametric determination may
include selecting quantities Such as the frequency, amplitude,
and phase components of the low frequency component of an
AMPWM signal based on such comparisons in an attempt to
achieve normal EEG presentation. By using pulse width
modulation for the purpose of varying the duty cycle of the
electrical signal of relatively high frequency, the time-aver
aged current deliverable by that signal can be controlled.
Therefore, further to this embodiment, the pulse width duty
cycle of the high frequency component of an AMPWM signal
is selected based on Such comparisons to affect the time
averaged current delivered by the AMPWM signal in an
attempt to achieve normal EEG presentation.
In one embodiment of this method of parametric determi
nation, the frequencies for the low frequency signal compo
nents of the electrical signal, such as an AMPWM signal, are
selected to modulate either excessive or diminished EEG

activity, as determined by the aforementioned comparative
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analysis. In other words, determining parametric values may
include selecting frequencies for low frequency signal com
ponents of an electrical tissue stimulation signal to modulate
either excessive or diminished EEG activity, as determined by
the comparative analysis. In this embodiment, if excessively
high frequency EEG activity were found in a region of the
brain, a lower frequency may be used as the low frequency
component of the electrical signal for stimulating that region
of the brain. In other words, selecting frequencies for low
frequency signal components may include selecting a lower
frequency as the low frequency component of the electrical
signal for stimulating a region of the brain where excessively
high frequency EEG activity is found, with a “lower fre
quency' being defined as between 1 and 20 hertz lower than
the value of the identified excessively high EEG frequency. In
practice, a progressively lower frequency might be used in
therapeutic activity until the excessive EEG activity in a
region of the brain reduces to a more normal level. In one
continually monitored during therapeutic activity, providing
an indication of the effectiveness of the therapeutic activity.
In embodiments of the present invention electrical stimu
lation signals such as AMPWM signals may be directed
through desired tissues or tissue regions by introducing Such
signals so as to cause current to flow through the desired
tissues or tissue regions. As shown in FIG. 24, this may be
accomplished by first placing any number of stimulating
leads 121 in proximity to the tissues or tissue regions to be
stimulated, and further placing any number of ground leads
120 in another proximity to the tissues or tissue regions to be
stimulated such that a vector path extends between stimulat
ing leads and ground leads and passes through the particular
tissues meant to receive electrical stimulation. In other words,
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at least one stimulating lead 121 and one ground lead 20 are
placed in proximity to a tissue region to be stimulated Such
that a vector path extending between the stimulating lead and
the ground lead passes through the tissue region to be stimu
lated. An electrical stimulation signal is then introduced
through the at least one stimulating lead such that current is
caused to flow along the vector path through the tissue region
between the stimulating lead and the ground lead.
Thus, any number of stimulating leads may, for example,
be placed in proximity to the brain tissues where abnormal
EEG activity has been determined to exist. Further, any
appropriate number of ground leads may be placed in further
proximity to the brain tissues so as to create a vector that
extends between stimulating leads and ground leads and that
passes through the brain tissue to be stimulated. In this
arrangement, application of an electrical signal for stimulat
ing brain tissues will cause a current flow through Such brain
tissue, in an approximate vector direction between stimulat
ing leads and ground leads.
In another embodiment of parametric determination for the
purpose of stimulating a brain, a plurality of desirable stimu
lation frequencies may be determined by EEG analysis as
detailed above. As previously taught, a form of an AMPWM
signal may be generated by, for example, creating a low
frequency component waveform featuring multiple fre
quency components, as determined by inverse Fourier Trans
form methods. The plurality of desirable stimulation frequen
cies may be used to determine a single waveform of multiple
low frequency components by inverse Fourier Transform
computation, and may be used for creating an AMPWM
signal and may further be used for stimulating a brain, as
previously described. In other words, the application of
inverse Fourier Transform methods may include using
inverse Fourier Transform computation to determine from the
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plurality of desirable stimulation frequencies a single wave
form of multiple low frequency components, and the appli
cation of an electrical stimulation signal may include using
the single waveform to create and use an AMPWM signal to
stimulate brain tissue

In another embodiment of parametric determination for the
purpose of stimulating a brain, EEG data from brain tissue
may further be acquired during therapeutic tissue stimulation
signal application activity and analyzed at a time generally
concurrent to the stimulation signal being applied. In other
words, obtaining biopotential Voltage data may include
acquiring EEG data of brain tissue during therapeutic stimu
lation signal application activity, and determining parametric
values may include analyzing the EEG data as the stimulation
signal is being applied. Analysis of the EEG may include the
use of one or more of those methods previously described for
EEG acquired from brain tissue prior to stimulating the brain,
for example. Based on this analysis, comparisons may be
made between the acquired EEG presentation and a desired
EEG in a normal presentation. In this alternate embodiment,
quantities such as the frequency, amplitude and phase com
ponents of the low frequency component of an AMPWM
signal may be altered based on these comparisons in an
attempt to achieve a normal EEG presentation. In this imple
mentation, the pulse width duty cycle of the high frequency
component of an AMPWM signal may be altered based on the
comparisons to affect the time averaged current delivered by
the AMPWM signal in an attempt to achieve normal EEG
presentation.
In yet another embodiment of parametric determination for
the purpose of stimulating a brain, any number of sensory
inputs other than EEG data may be substituted in the methods
described herein to enable quantifying of the condition of
tissues or any other functional state of a Subject. In other
words, determining parametric values may include obtaining
sensory inputs quantifying the functional state of a subject,
and then determining parametric values for the purpose of
stimulating brain tissue in response to the sensory inputs.
Such sensory inputs may include, but are not limited to, tissue
impedance, temperature, oxygen Saturation, EMG activity,
electrocardiographic activity, biochemical levels, and/or
measures involving respiration patterns.
Further to the methods disclosed for deriving quantities
Such as the frequency, phase, pulse width duty cycle, and
amplitude of electrical signals for stimulating tissues, such as
an AMPWM signal, a number of methods may be used for
controlling the application time of the signals.
For example, the amount of time that an electrical signal for
stimulating tissues is to be applied to a Subject may be pre
determined and set programmatically based on empirical evi
dence gained from clinical experience, and then controlled by
Software to start and stop the application of the signal.
Alternatively, software may be provided to start an electri
cal signal for stimulating tissues and to stop the signal appli
cation automatically, as certain measures in tissue electrical
properties are achieved. In other words, controlling signal
application time may include starting and then automatically
stopping an electrical tissue stimulation signal in response to
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the achievement of certain desired measures of tissue electri

cal properties. With reference to the method of stimulating
brain tissues taught herein, the EEG of the brain may be
further acquired during the therapeutic activity and analyzed
at a time generally concurrent with the stimulation signal
being applied. The electrical signal application may be
stopped when any number of predetermined EEG properties
is achieved. In other words, controlling signal application
time may include acquiring EEG data from brain tissue dur
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ing therapeutic electrical tissue stimulation activity, analyZ
ing the acquired EEG data as the stimulation signal is being
applied, and stopping the electrical signal application when
one or more predetermined EEG properties are achieved. This
alternative method may include termination of signal appli
cation in response to one or more other measures of sensory
input including, but not limited to, tissue impedance, tem
perature, oxygen Saturation, EMG activity, electrocardio
graphic activity, biochemical levels, and measures involving
respiration patterns.
Alternatively, and as shown in FIG. 21, automation of
signal termination based on sensory input may be combined
with predetermination of a time for signal application, Such
that the electrical signal will not exceed a predetermined time
if desired electrical properties of the tissue are not achieved.
Generally, each of the methods disclosed can be applied to
tissues that are not brain tissues. Such as tissues including, but
not limited to, muscles, bones, tendons, ligaments, cartilage,
fascia, dermis (i.e., layers of skin), and/or internal organs.
Parametric determination generally relies on first taking mea
Sures of tissue electrical properties prior to application of any
electrical signal for the purposes of stimulating the tissues.
Upon collection of tissue electrical property data, an analysis
for the purpose of making statistical comparisons between the
findings and measures known to represent normal tissue elec
trical properties in a healthy normal population of living
beings, including human beings, may be performed. In other
words, a method is provided for electrically stimulating tissue
in which parametric values of an electrical tissue stimulation
signal may be determined by first taking measures of electri
cal properties of a region of tissue to be stimulated, making
statistical comparisons between the measures and measures
known to represent normal tissue electrical properties in a
healthy normal population of living beings, determining para
metric values of an electrical tissue stimulation signal in
response to the comparisons, and then generating and apply
ing to the region of tissue an electrical stimulation signal
having the determined parametric values.
In embodiments of the present invention, the method of
parametric determination is completed as quantities such as
the frequency, amplitude and phase components of the low
frequency component of an AMPWM signal are selected
based on Such comparisons, in an attempt to achieve normal
tissue electrical property presentation. By using pulse width
modulation for the purpose of varying the duty cycle of a high
frequency component of an AMPWM signal, the time-aver
aged current deliverable by that signal can be controlled.
Thus, the pulse width duty cycle of the high frequency com
ponent of an AMPWM signal may be selected, based on these
comparisons, to affect the time averaged current delivered by
the AMPWM signal, in an attempt to achieve normal tissue
electrical property presentation.
As described further above, in directing the electrical sig
nals for the purpose of stimulating tissues, in embodiments of
the present invention, the electrical signal may be introduced
So as to cause current to flow through Such tissues, involving
first placement of any number of stimulating leads 121 in
proximity to the tissues, and further by placing any Suitable
number of ground leads 120 in another proximity to the
tissues. In one placement pattern, a vector direction between
stimulating leads 121 and ground leads 120 passes through
the particular tissues meant to receive electrical stimulation.
Thus, stimulation of tissues other than a brain may be
accomplished by placing any appropriate number of stimu
lating leads 121 in proximity to the tissues. Correspondingly,
any suitable number of ground leads 120 are placed in further
proximity to the tissues, so as to create a vector direction
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between stimulating leads 121 and ground leads 120 that
passes through the particular tissue to be stimulated. In this
arrangement, application of an electrical signal for stimulat
ing tissues will cause a current flow through the tissues, in an
approximate vector orientation between electrodes 122 of
stimulating leads 121 and ground leads 120.
In yet another embodiment of parametric determination for
the purpose of using electrical signals for stimulating tissues,
including brain tissues and tissues that are not brain tissues, a
measure of biochemicals, particularly neurochemicals and
neurotransmitters, may first be taken from tissues and/or flu
ids relevant to the tissues to be stimulated. The measures are
then analyzed by, for example, making comparisons between
the findings of the measure of biochemicals and similar mea
sures known to represent normal levels of the biochemicals in
a healthy normal population of living beings, including
human beings. Such comparisons may be done for the pur
pose of quantifying differences that indicate either excessive,
that is, greater amounts of certain biochemicals than normal,
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late diminished levels of the neurotransmitter serotonin, the

10

15

or diminished, that is, lower amounts of certain biochemicals

than normal. In other words, a method is provided that may
include determining parametric values of an electrical tissue
stimulation signal by taking measures of biochemicals from
tissues and/or fluids relevant to the tissues to be stimulated,

analyzing the measures, and determining parametric values
of an electrical tissue stimulation signal in accordance with
the analysis of the measures. An electrical stimulation signal
may then be generated and applied to the region. The applied
signal may have the determined parametric values and may be
configured to reduce tissue impedance and increase depth of
signal penetration.
As shown in FIG. 23, an embodiment of parametric deter
mination may further include determination of molecular
resonant frequencies associated with biochemicals deter
mined to be excessive or diminished in a subject. In this
embodiment, an electrical signal for stimulating tissues may
be applied for the purpose of affecting abnormal biochemical
levels. In other words, determining parametric values in
response to the comparisons may include determining elec
trical signal parameters that will tend to normalize abnormal
biochemical levels when Such a signal is generated and
applied to the Subject.
Parametric determination, in these embodiments, may
include selecting quantities Such as the frequency, amplitude,
and/or phase components of the low frequency component of
an AMPWM signal, based on the molecular resonant frequen
cies associated with biochemicals to be used, in an attempt to
achieve normal biochemical presentation. The pulse width
duty cycle of the high frequency component of an AMPWM
signal may be selected based on Such comparisons, to affect
time averaged current delivered by the AMPWM signal, in an
attempt to achieve normal biochemical presentation. In one

25

mitted to a remote location, via a network, such as the Internet
or via another communication medium.
30
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As shown in FIG. 25, analysis and comparisons, similar to
those described above, may be performed at the remote loca
tion for the purpose of determining quantities such as the
frequency, phase, pulse width duty cycle, amplitude, start
time, and stop time parameters of electrical signals for stimu
lating tissues, such as an AMPWM signal. The parameters for
an electrical signal for stimulating tissues may then be trans
mitted from the remote location, via a network, Such as the
Internet or via other communication medium, to an electrical
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stimulation apparatus as taught herein, and used in the thera
peutic application of the electrical signal on a Subject. In other
words, a method is provided for electrically stimulating tissue
that may include the determination of parametric values of an
electrical tissue stimulation signal by taking measures of
electrical properties of a Subject, then transmitting the mea
Sures to a remote location via a network Such as the Internet,
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embodiment of the invention, the involved biochemical levels

can be continually or periodically monitored during therapeu
tic activity, providing an indication of the effectiveness of the
therapeutic activity.
In yet another embodiment of parametric determination
that relies on making comparisons between the findings of
abnormal biochemical levels in a subject, the determination
of the frequencies for the low frequency signal component of
an electrical signal, such as an AMPWM signal, may be made
based on empirical findings of frequencies that are known to
be relevant to stimulating the biochemicals, the frequencies
being those potentially different than resonant frequencies
associated with the biochemicals. For example, the frequen
cies for the low frequency signal component of an electrical
signal, such as an AMPWM signal, may be selected to modu

diminished levels being common to Such conditions as
depression and chronic pain, as determined by the aforemen
tioned comparative analysis. In various examples of pub
lished literature, production of serotonin has been shown to
be increased by stimuli at a frequency of between about one
and 60 hertz, more preferably at about 10 hertz. In accordance
with the method taught herein, the low frequency component
of an AMPWM signal may therefore be selected to be
between about one and 60 hertz, more preferably about 10
hertz, in an attempt to increase serotonin production.
A number of methods are provided for deriving, setting and
altering quantities or parameters such as the frequency, phase,
pulse width duty cycle, and/or amplitude of electrical signals
for stimulating tissues, such as an AMPWM signal, wherein
information may be transmitted between an electrical stimu
lation apparatus as taught herein and a remote location.
According to one Such method, measures of electrical
parameters used to quantify the condition of tissues or any
other appropriate functional State of a Subject may first be
obtained as described above. Such electrical parameters may
include, but are not limited to, tissue impedance, temperature,
oxygen saturation, EEG activity, EMG activity, electrocar
diographic activity, biochemical levels, and/or measures
involving respiration patterns. These measures may be trans
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analyzing the measures at the remote location by, for
example, making statistical comparisons between the mea
Sures and measures known to represent normal tissue electri
cal properties in a healthy normal population of living beings,
remotely determining parametric values of an electrical tissue
stimulation signal in response to the analysis, transmitting the
parametric values from the remote location via a network
Such as the Internet to an electrical stimulation apparatus, and
causing the electrical stimulation apparatus to generate and
apply to a region of the Subjects tissue an electrical stimula
tion signal, e.g., a signal. Such as an AMPWM signal, con
figured to reduce tissue impedance and increase depth of
signal penetration, and having the remotely determined para
metric values.
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Alternatively, according to this method, measures of elec
trical parameters that are used to quantify the condition of
tissues or other appropriate functional state of a Subject may
be acquired during the therapeutic activity at a time generally
concurrent to the application of the stimulation signal. Such
electrical parameters may include, but are not limited to,
tissue impedance, temperature, oxygen Saturation, EEG
activity, EMG activity, electrocardiographic activity, bio
chemical levels, and/or measures involving respiration pat
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terns. These measures may be transmitted to a remote loca
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FIG. 26 shows an exemplary flow diagram of exemplary
action in accordance with one such method. As shown in FIG.

tion, via a network, such as the Internet or via other
communication medium.

Analysis and comparisons as described herein may be per
formed at the remote location for the purpose of altering
quantities such as the frequency, phase, pulse width duty
cycle, amplitude, start time, and/or stop time parameters of
electrical signals for stimulating tissues, such as an AMPWM
signal. The determined parameters for altering an electrical
signal for stimulating tissues may be transmitted from a

10

remote location, via a network, Such as the Internet or via
other communication medium, to an electrical stimulation

apparatus as taught herein, and used in the further therapeutic
application of the altered electrical signal on a Subject. In
other words, taking measures may include acquiring mea
Sures of electrical parameters from a subject as a stimulation
signal is being applied to the Subject, and remotely determin
ing includes altering quantities such as the frequency, phase,
pulse width duty cycle, amplitude, start time, and/or stop time
parameters of electrical tissue stimulation signals in response
to Such measures taken as a stimulation signal is being
applied.
The analysis and comparisons as taught herein may be
performed at the remote location for the purpose of determin
ing changes in the electrical parameters over time, in accor
dance with the application of therapeutic activities. Parameter
changes overtime may be transmitted from a remote location,

15

at the location in which the measurements are taken, or at a
remote location to which the measurements have been trans
mitted.
25

via a network, Such as the Internet, or via other communica

tion medium, to a subjector a person of sufficient competence
Such as a physician, and used to provide an indication of
changes in the electrical parameters over time, in accordance
with the application of therapeutic activities.
In addition, symptom data may be acquired from a subject

30

and transmitted via a network, such as the Internet, or via
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another communication medium, from a subject or a person
of Sufficient competence, such as a physician, to the remote
location for the purpose of tracking changes in Symptoms
associated with a condition of the Subject over time, in accor
dance with the application of therapeutic activities. In other
words, symptom data may be acquired from a subject, trans

26, in step S1, biophysical activity such as but not limited to
biopotential voltages such as EEG and EMG may be mea
sured in a portion of the subject’s body that is to be treated.
This portion of the body to be treated may include a portion of
the subjects brain, the subjects entire brain, body tissue
containing an injury, body tissue near a bone injury, body
tissue near a muscle injury, body tissue involved in or near a
painful condition, and/or body tissue near a nerve causing
health issues for example.
As shown in step S2, the measured biophysical activity
may be compared to normal biophysical activity for that
portion of the body. The analysis of biophysical activity may
involve either biophysical values from individual sites or
multiple sites. The analysis may include statistical analyses of
biophysical Voltages, their frequency components, and/or
their phase components. In addition, the statistical analysis
may include measures of variance, correlation, and/or coher
ence. This step, either alone or in connection with steps S3
and S4, as described further below, may be performed either
As shown in step S3, the site to which electrical stimulation
will be applied may be determined, based on, for example,
regions where the measured biophysical levels differ from the
normal, desired biophysical activity. The differences in the
biophysical levels are quantified and treatment sites may
include regions where the frequency or amplitude compo
nents of the subject’s biophysical levels exhibit greater values
than normal, lower values than normal, and/or values that
fluctuate more than normal. The site to which the electrical
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signal is to be applied may include muscles, bones, tendons,
ligaments, cartilage, fascia, dermis, and/or internal organs.
As shown in step S4, electrical parameters including, but
not limited to, the frequency, phase, pulse width duty cycle,
and amplitude may be determined for the electrical signal to
be applied to the Subject, based on, for example, the analysis
performed in step S2, to attempt to bring the subjects bio
physical values for the determined site to more normal,

mitted to the remote location via a communication medium

desired values.

Such as the Internet, and recorded at the remote location.

As shown in step S5, at least one stimulating lead may be
placed in proximity to the determined site. As shown in step
S6, at least one ground lead may be placed so as to create a
vector direction between the stimulating lead and the ground
lead that passes through the site to be treated. In this manner,
the path of the electrical stimulation will pass through the site
to be treated. Any Suitable number of stimulation and ground
leads may be used.
As shown in step S7, an electrical signal may be applied
through the leads, the electrical signal having the determined
parameters such as, but not limited to, frequency, phase, pulse
width duty cycle, and/or amplitude. The electrical signal may
be, for example, an AMPWM signal, general examples of
which are shown in FIGS. 7, 9, and 11, wherein the signal
includes a high frequency signal component that is amplitude
modulated by one or more low frequency components and
further pulse width modulated. The high frequency signal
component may be selected, for example, to overcome tissue
impedance, and a low frequency signal component may pref
erably be selected for its therapeutic effect. By using pulse
width modulation for the purpose of varying the duty cycle of
the electrical signal of relatively high frequency, the time
averaged current deliverable by that signal can be controlled.
Therefore, the pulse width duty cycle of the high frequency
component may be selected, based on the analysis in S2, to

Changes in the Subject's symptoms may be tracked by repeat
ing the acquiring, transmitting, and recording of data on the
Subjects symptoms. This symptom data may be compared to
measures of electrical parameters acquired, and transmitted
to a remote location either (a) periodically during the thera
peutic activity, or (b) at a time generally concurrent with the
stimulation signal being applied, as taught herein. A compari
Son of symptom data and changes in electrical parameters
may be made and transmitted from a remote location, via a
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network, such as the Internet, or via other communication

medium, to a subject or a person of Sufficient competence
Such as a physician, and used for the purpose of providing
indication of changes in the symptoms over time in accor
dance with the application of therapeutic activities.
In accordance with the methods taught hereinforproviding
feedback and information about changes in electrical param
eters and/or symptoms, such feedback may include, but is not
limited to, methods involving statistics or graphical represen
tations of Such changes, any method of visually illustrating
the changes, and any method of audibly illustrating the
changes.
A number of methods are provided for treatment of various
conditions using electrical signals for stimulating tissues,
such as an AMPWM signal.
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affect the time averaged current delivered by the AMPWM
signal. The low frequency component of the electrical signal
may be selected to modulate the excessive, diminished, and/
or variable biophysical activity at the determined site. The
low frequency component of the AMPWM signal may
include multiple frequency components. An AMPWM signal
with multiple low frequency components is shown in FIG. 11.
As shown in step S8, information may be acquired from a
sensory input generally concurrent with the application of the
electrical signal, to quantify the condition of either the site
being treated with the electrical signal or the functional state
of the Subject being treated. Such sensory inputs may include
measures of biophysical activity, including but not limited to
EEG, EMG, tissue impedance, temperature, oxygen satura
tion, electrocardiographic activity, biochemical levels, and/or
respiratory patterns. This monitoring of sensory inputs may
occur as a continual process throughout the therapeutic appli
cation of the electrical signal. Biophysical activity of the
Subject may be sampled at times of minimal electrical stimu
lation signal amplitude, Such as at Zero amplitude.
As shown in Step S9, at least one characteristic parameter
of the electrical signal may be altered based on a comparison
of the information acquired from the sensory input and a
desired value in a normal Subject. Electrical signal parameters
Such as, but not limited to, the frequency, phase, pulse width
duty cycle, and/or amplitude of the electrical signal may be
altered. The application of the electrical signal may be
stopped based on certain measures in tissue electrical prop
erties being achieved. In addition, the particular leads used to
apply the electrical stimulation may be varied. The compari
son/analysis of the information acquired in step S8 may occur
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at the location at which the measurements are taken or at a

remote location to which the sensory input information has
been transmitted.

A central nervous system condition of a Subject may be
treated by Stimulating tissues in close proximity to the vagus
nerve using an AMPWM signal. In one arrangement of lead
placement, an electrode 122 of any stimulating lead 121 may
be adapted to be placed at the posterior base of the neck of the
subject near the first, second, or third cervical vertebrae. An
electrode 122 of a ground lead 20 may be adapted to be placed
on tissue in a position creating a vector between electrodes
122 that passes near the vagus nerve.
Abrain of a subject may be treated by stimulating tissues in
close proximity to the vagus nerve using an AMPWM signal.
In one arrangement of lead placement, an electrode 122 of any
stimulating lead 121 may be adapted to be placed at the
posterior base of the neck of the subject near the first, second,
or third cervical vertebrae. An electrode 122 of a ground lead
20 is adapted to be further placed on tissue, creating a vector
between electrodes 122 that passes near the vagus nerve.
Alternatively, a brain of a subject may be treated using an
AMPWM signal. In one arrangement of lead placement, an
electrode 122 of any stimulating lead 121 may be adapted to
be placed on tissue of the subject near an area of the brain
identified as having a dysfunction, such as, but not limited to,
identification by EEG analysis. An electrode 122 of a ground
lead 20 may be adapted to be further placed on tissue near the
area of the brain identified as having a dysfunction, creating a
vector between electrodes 122 that passes through the area of
the brain identified as having the dysfunction.
Tissues containing an injury may also be treated using an
electrical tissue stimulation signal that reduces tissue imped
ance and increases depth of signal penetration, such as an
AMPWM signal. In one arrangement of lead placement, an
electrode 122 of any stimulating lead 121 may be adapted to
be placed on tissue of the subject near the location of the
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injury. An electrode 122 of a ground lead 20 may be adapted
to be further placed on tissue near the location of the injury,
creating a vector between electrodes 122 that passes through
the injury.
Tissues containing an injury involving a bone may also be
treated using a signal. Such as an AMPWM signal, configured
to reduce tissue impedance and increase signal penetration
depth. In one arrangement of lead placement, an electrode
122 of any stimulating lead 121 may be adapted to be placed
on tissue of a subject near the bone injury. An electrode 122 of
a ground lead 20 may be adapted to be further placed on tissue
near the bone injury, creating a vector between electrodes 122
that passes through the bone injury.
Tissues containing an injury involving a muscle may also
be treated using a signal. Such as an AMPWM signal, config
ured to reduce tissue impedance and increase signal penetra
tion depth. In one arrangement of lead placement, an elec
trode 122 of any stimulating lead 121 may be adapted to be
placed on tissue of the Subject near the muscle injury. An
electrode 122 of a ground lead 20 may be adapted to be further
placed on tissue near a muscle injury, creating a vector
between electrodes 122 that passes through the muscle injury.
Muscle tissues containing a painful condition for a Subject,
Such as a myofascial trigger point, may also be treated using
a signal. Such as an AMPWM signal, configured to reduce
tissue impedance and increase signal penetration depth. In
one arrangement of lead placement, an electrode 122 of any
stimulating lead 121 may be adapted to be placed on tissue of
the Subject near the muscle containing a painful condition,
Such as a myofascial trigger point. An electrode 122 of a
ground lead 20 may be adapted to be further placed on tissue
near the muscle containing a painful condition, creating a
vector between electrodes 122 that passes through the muscle
containing a painful condition; i.e., through the myofascial
trigger point.
A myofascial trigger point may also be treated using a
signal, such as an AMPWM signal, configured to reduce
tissue impedance and increase signal penetration depth. In
one arrangement of lead placement, an electrode 122 of any
stimulating lead 121 may be adapted to be placed on tissue of
a subject near a myofascial trigger point. An electrode 122 of
a ground lead 20 may be adapted to be further placed on tissue
near a myofascial trigger point, creating a vector between
electrodes 122 that passes through the myofascial trigger
point.
Myofascial pain may also be treated using an electrical
tissue stimulation signal that reduces tissue impedance and
increases depth of signal penetration, such as an AMPWM
signal. In one arrangement of lead placement, an electrode
122 of any stimulating lead 121 may be adapted to be placed
on tissue of a subject near the location of myofascial pain. An
electrode 122 of a ground lead 20 may be adapted to be further
placed on tissue near the location of myofascial pain, creating
a vector between electrodes 122 that passes through the tissue
involved in myofascial pain.
Conditions associated with central nervous system dys
function may be treated with an electrical tissue stimulation
signal that reduces tissue impedance and increases depth of
signal penetration, such as an AMPWM signal. Such condi
tions may include but are not limited to fibromyalgia Syn
drome, chronic pain, traumatic brain injury, affective disor
ders, such as attention deficit disorder (ADD) and attention
deficit hyperactivity disorder (ADHD), chronic fatigue, sleep
disorders, obsessive compulsive disorder, Tourette Syn
drome, depression, anxiety, and addiction.
Conditions associated with abnormal levels of biochemi

cals including, but not limited to neurotransmitters and/or
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neurochemicals in tissues, may be treated with an electrical
signal for tissue stimulation that reduces tissue impedance
and increases depth of signal penetration, Such as an
AMPWM signal. Such conditions may include, but are not
limited to, fibromyalgia syndrome, chronic fatigue, obesity,
chronic pain, muscle pain, myofascial pain, myofascial trig
ger points, and psychological conditions. Such as depression.
Conditions may be treated by using an electrical tissue
stimulation signal that reduces tissue impedance and
increases depth of signal penetration, such as an AMPWM
signal, to enhance a body's own healing mechanisms. Such
conditions may include, but are not limited to, broken bones,
injured tissues, post-Surgical wounds, cuts, muscle pain asso
ciated with strains, and spasms.
An electrical signal that reduces tissue impedance and
increases depth of signal penetration, such as such as an
AMPWM signal, may also be used for tissue stimulation for
purposes of reducing fatigue, increasing alertness, or increas
ing mental clarity. In other words, a method for improving a
body's function is provided that includes applying an electri
cal tissue stimulation signal to a Subject, where the signal is
configured and applied in Such a way as to produce one or
more beneficial effects Such as reducing fatigue, increasing
alertness, and increasing mental clarity.
An electrical tissue stimulation signal, e.g., a signal. Such
as an AMPWM signal, that reduces tissue impedance and
increases depth of signal penetration, may also be used for
tissue stimulation for purposes of enhancing performance
measures associated with, but not limited to, sporting activi
ties, academic activities, and similar competitive endeavors.
An electrical signal, such as an AMPWM signal, that
reduces tissue impedance and increases depth of signal pen
etration, may also be used for tissue stimulation for purposes
of advantageously enhancing the function of organs. In one
illustrative method, an AMPWM signal may be used to stimu
late pancreatic tissues so as to enhance production of insulin,
thereby affecting conditions such as diabetes.
For various methods and apparatus taught herein, treat
ment times may range between about 1 second and about 60
minutes, with low frequency components of an AMPWM
signal ranging between about 1 hertz and about 200 hertz, and
high frequency components of an AMPWM signal ranging
between about 100 hertz and about 1,000,000 hertz. The duty
cycle of an AMPWM signal may range between about 1
percent and about 99 percent, and assessment periods used for
the purpose of analyzing acquired biopotential Voltages and
selectively switching the use of leads may range between
about 1 second and about 60 seconds.

The following references are incorporated by reference in
their entirety:
1. “High-frequency stimulation of the subthalamic nucleus
silences Subthalamic neurons: a possible cellular mechanism
in Parkinson's Disease'. Magarinos-Ascone C, Pazo J. H
Macadar O and Buno W. (Neuroscience 2002: 115(4): 1109
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5. "Centromedian-thalamic and hippocampal electrical
stimulation for the control of intractable epileptic seizures'.
Velasco M, Velasco F, Velasco AL. J. Clin Neurophysiol 2001
November; 18(6):495-513
The invention is not limited in any way to the embodiments
described herein. In this regard, no attempt is made to show
structural details of the invention in more detail than is nec

essary for a fundamental understanding of the method of the
invention. The description is intended only to make apparent
10

tion may be embodied in practice.
I claim:
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pathic pain, Tronnier V. Schmerz 2001 August; 15(4):278-9.

8. A tissue stimulation apparatus as set forth in claim 4 in
which the external computing device is configured to func
tionally interface with at least one other network computing
device.
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9. A tissue stimulation apparatus as set forth in claim 8 in
which the external computing device is configured to func
tionally interface with at least one of the other network com
puting devices via the Internet.
10. A tissue stimulation apparatus as set forth in claim 9 in
which the external computing device is configured to func
tionally interface with at least one of the other network com
puting devices to determine parametric values of an electrical
tissue stimulation signal, and to receive Subsequent corre
sponding control data from the other network computing
device via the functional interfaces.

60

3. "The anticonvulsant effect of electrical fields'. Wein
4. "Electrical stimulation of the motor cortex in neuro

7. A tissue stimulation apparatus as set forth in claim 4 in
which the external computing device is configured to estab
lish parameters of the electrical signals generated by the
device.

16261-6.

stein S, Curr Neurol Neurosci Rep 2001 March; 1(2):155-61.

1. A tissue stimulation apparatus comprising an electrical
stimulation device that includes a stimulation signal genera
tion circuit configured to generate an electrical tissue stimu
lation signal comprising a therapeutic signal component and
a penetration signal component wherein the penetration sig
nal component is configured to reduce tissue impedance and
increase depth of Stimulation signal penetration.
2. A tissue stimulation apparatus as set forth in claim 1 in
which the stimulation signal generation circuit is configured
to generate an amplitude modulated pulse width modulated
(AMPWM) signal.
3. A tissue stimulation apparatus as set forth in claim 1 in
which the stimulation signal generation circuit comprises a
processor configured to control generation of electrical sig
nals by the electrical stimulation device for tissue stimulation.
4. A tissue stimulation apparatus as set forth in claim 3 in
which the tissue stimulation apparatus includes an external
computing device electrically coupled to the processor and
configured to provide a user interface.
5. A tissue stimulation apparatus as set forth in claim 4 in
which the external computing device is configured to
exchange data and control signals with the processor.
6. A tissue stimulation apparatus as set forth in claim 4 in
which the external computing device is configured to allow a
user to modify operational parameters of the electrical stimu
lation device.

17.

2. “The spatial receptive field of thalamic inputs to single
cortical simple cells revealed by the interaction of visual and
electrical stimulation', Kara, Pezaris J. S. Yurgenson S and
Reid, R. C. Proc Natl Acad Sci USA 2002 Dec. 10; 99(25):

to those skilled in the art how the several forms of the inven
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11. A tissue stimulation apparatus as set forth in claim 3 in
which the stimulation signal generation circuit further com
prises a digital-to-analog (D/A) converter configured to
receive signal parameters from the processor and to generate
a corresponding analog Voltage representing an electrical sig
nal for stimulating tissues.
12. A tissue stimulation apparatus as set forth in claim 11 in
which the stimulation signal generation circuit further com
prises a signal conditioning and amplification circuit config
ured to receive the analog voltage from the D/A converter and
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has been coupled via the lead test port to the processor, by
comparing the electrical signal of known properties to the
signal conducted through that lead.
22. A tissue stimulation apparatus as set forth in claim 1 in
which the tissue stimulation apparatus includes one or more
external stimulation devices electrically coupleable to the

43
to generate a generally equivalent signal having one or more
advantageous enhancements selected from the group of
enhancements consisting of increased Voltage amplitude,
decreased signal-to-noise ratio, and increased current capa
bility.
13. A tissue stimulation apparatus as set forth in claim 12 in
which the tissue stimulation apparatus includes a plurality of
stimulation leads and one or more ground leads configured to
conduct electrical energy between tissues and the electrical
stimulation device.

electrical stimulation device.

23. A tissue stimulation apparatus as set forth in claim 22 in
which the one or more external stimulation devices include
10

14. A tissue stimulation apparatus as set forth in claim 13 in
which the stimulation signal generation circuit is configured
to selectively control the delivery of stimulating electrical
signals to tissues through one or more selected ones of the
stimulation leads.

15. A tissue stimulation apparatus as set forth in claim 14 in
which the stimulation signal generation circuit further
includes a stimulation Switching circuit electrically coupled
to the processor, the processor and stimulation Switching
circuit being configured to Switch signals from the signal
conditioning and amplification circuit to independent electri
cal conduction paths that are electrically coupled with the
respective stimulation leads.
16. A tissue stimulation apparatus as set forth in claim 15 in
which the stimulation signal generation circuit further
includes a first ground Switching circuit electrically coupled
with the independent electrical conduction paths and with the
processor, the processor and ground Switching circuit being
configured to selectively Switch the independent conduction
paths to at least one system ground point.
17. A tissue stimulation apparatus as set forth in claim 1 in

electromechanical device, and an audio device.

24. A tissue stimulation apparatus as set forth in claim 22 in
which the one or more external stimulation devices include an
15

optical device comprising one or more displays for showing
images.
26. A tissue stimulation apparatus as set forth in claim 22 in
which the one or more external stimulation devices include an
25
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which the electrical stimulation device includes at least one

auxiliary control I/O connector electrically coupled with an
input-output (I/O) port of the processor, the processor and
control I/O connector being configured to provide control
signals between the processor and a peripheral device.
19. A tissue stimulation apparatus as set forth in claim 13 in
which the apparatus includes at least one lead test port elec
trically coupled to the processor and configured to electrically
couple a conduction interface of one of the leads to the pro
cessor, the processor being configured to test the electrical
conducting integrity of the lead whose conduction interface
has been coupled via the lead test port to the processor.
20. A tissue stimulation apparatus as set forth in claim 19 in
which the processor is configured to output an electrical sig
nal of known properties to the lead whose conduction inter
face has been coupled via the lead test port to the processor,
and to acquire and test the resulting electrical signal con
ducted through that lead and returned to the processor
through the lead test port.
21. A tissue stimulation apparatus as set forth in claim 20 in
which processor is configured to determine the electrical
conducting integrity of the lead whose conduction interface

28. A tissue stimulation apparatus as set forth in claim 13 in
which the tissue stimulation apparatus includes a biopotential
acquisition device configured to measure biopotential Voltage
of tissues to be stimulated.

is not desired.

18. A tissue stimulation apparatus as set forth in claim 17 in

audio device adapted to play music.
27. A tissue stimulation apparatus as set forth in claim 1 in
which the tissue stimulation apparatus includes data collec
tion instruments configured to collect data on a subject during
periods of therapy and electrically coupled to the electrical
stimulation device.

a battery connected to other circuits of the apparatus and
configured to provide electrical power to other circuits
of the electrical stimulation device;

optical device comprising eyeglasses adapted to carry illumi
nating devices.
25. A tissue stimulation apparatus as set forth in claim 22 in
which the one or more external stimulation devices include an

which the electrical stimulation device includes:

a battery charger and Switching circuit electrically coupled
to the battery; and
a processor electrically coupled to the battery charger and
Switching circuit, the processor being configured to
command the battery charger and Switching circuit to
decouple the device from an external power source when
isolation is desired and to couple the external power
source to the battery to charge the battery when isolation

one or more devices selected from the group of devices con
sisting of an optical device, an electromagnetic device, and
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29. A tissue stimulation apparatus as set forth in claim 28 in
which the biopotential acquisition device includes an ampli
fier module comprising a biopotential amplifier.
30. A tissue stimulation apparatus as set forth in claim 29 in
which the biopotential acquisition device includes at least one
biopotential acquisition lead and at least one ground lead.
31. A tissue stimulation apparatus as set forth in claim 30 in
which the biopotential amplifier module is electrically cou
pleable to the electrical stimulation device through anyone or
more connectors selected from the group of connectors con
sisting of stimulation lead connectors, auxiliary power Supply
connector, control I/O connectors, and auxiliary I/O connec
tors of the electrical stimulation device.

32. A tissue stimulation apparatus as set forth in claim 31 in
which the biopotential acquisition device is configured to
measure anyone or more biopotential Voltages selected from
the group of biopotential Voltages consisting of electroen
cephalographic (EEG) Voltage, electromyographic (EMG)
Voltage, and electrocardiographic Voltage.
33. A tissue stimulation apparatus as set forth in claim 30 in
which the tissue stimulation apparatus is configured for the
biopotential amplifier to measure biopotential Voltage of tis
Sue as the electrical stimulation device provides stimulation
to the tissue.
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34. A tissue stimulation apparatus as set forth in claim 33 in
which the biopotential acquisition device includes at least one
inductor electrically coupled to the electrical stimulation
device and operatively coupleable to at least one biopotential
acquisition lead, the electrical stimulation device and the at
least one inductor being configured to deliver tissue stimula
tion signals through the at least one biopotential acquisition
lead.
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35. A tissue stimulation apparatus as set forth in claim 33 in
which the biopotential acquisition device includes one or
more inductors electrically coupled to the electrical stimula
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tion device and operatively coupleable to one or more respec
tive biopotential acquisition leads, the electrical stimulation
device and inductors being configured to selectively deliver
tissue stimulation signals through the one or more biopoten
tial acquisition leads.
36. A tissue stimulation apparatus as set forth in claim 33 in
which the biopotential acquisition device includes at least one
adjunct Switching circuit and an adjunct Switching control
electrically coupled to the electrical stimulation device, the
adjunct Switching circuit being operatively coupleable to at
least one biopotential acquisition lead, the electrical stimula
tion device and an adjunct Switching control being configured
to selectively connect the electrical stimulation device to
selected leads to transmit tissue stimulation signals to the
selected leads and to connect selected leads to the biopoten
tial amplifier to transmit biopotential voltages to the biopo
tential amplifier.
37. A tissue stimulation apparatus as set forth in claim 30 in
which the electrical stimulation device is configured to use at
least one biopotential acquisition lead for both acquiring bio
potential Voltage and delivering an electrical tissue stimula
tion signal.
38. A tissue stimulation apparatus as set forth in claim 37 in
which the electrical stimulation device is configured to use at
least one biopotential acquisition lead for simultaneously
acquiring biopotential Voltage and delivering an electrical
tissue stimulation signal.
39. A tissue stimulation apparatus as set forth in claim38 in
which the electrical stimulation device is configured to selec
tively sample biopotential voltage data from the biopotential
acquisition device at times of minimal electrical stimulation
signal amplitude.
40. A tissue stimulation apparatus as set forth in claim 39 in
which the electrical stimulation device is configured to selec
tively sample biopotential voltage data from the biopotential
acquisition device over assessment periods of between about
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47. A tissue stimulation apparatus as set forth in claim 46 in
which the biopotential acquisition device is an EEG acquisi
tion device and the external computing device is configured to
determine parametric value of an electrical tissue stimulation
signal in response to EEG data obtained by the EEG acqui
sition device and to send corresponding control data to the
processor.
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circuit.
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I second and about 60 seconds.

41. A tissue stimulation apparatus as set forth in claim 39 in
which the electrical stimulation device is configured to selec
tively sample biopotential voltage data from the biopotential
acquisition device at times of minimal electrical stimulation
signal amplitude within the period of a high frequency signal
component of an AMPWM signal.
42. A tissue stimulation apparatus as set forth in claim 1 in
which the electrical stimulation device is configured to select
the frequencies of a high frequency signal component of an
AMPWM signal to be multiples of integral powers of two.
43. A tissue stimulation apparatus as set forth in claim 42 in
which the electrical stimulation device is configured to select
the frequencies of a high frequency signal component of an
AMPWM signal to be integral multiples of 256.
44. A tissue stimulation apparatus as set forth in claim 42 in
which the electrical stimulation device is configured to math
ematically analyze acquired biopotential Voltage data using a
Fourier Transform analysis whereupon a number of Samples
per second is equal to an integral power of two.
45. A tissue stimulation apparatus as set forth in claim 30 in
which the tissue stimulation apparatus is configured to use
biopotential Voltage data to determine parametric values of an
electrical tissue stimulation signal.
46. A tissue stimulation apparatus as set forth in claim 45 in
which an external computing device is configured to deter
mine parametric value of an electrical tissue stimulation sig
nal in response to biopotential Voltage data obtained by the
biopotential acquisition device and to send corresponding
control data to the processor.

48. A tissue stimulation apparatus as set forth in claim 46 in
which the tissue stimulation apparatus is configured to use at
least one biopotential acquisition lead as either a conduction
path for an electrical tissue stimulation signal, a conduction
path for carrying a biopotential Voltage to the biopotential
amplifier, or a ground.
49. A tissue stimulation apparatus as set forth in claim 48 in
which the processor is configured to selectively switch a
biopotential acquisition lead to an apparatus ground point by
sending corresponding control signals to the second ground
Switching circuit.
50. A tissue stimulation apparatus as set forth in claim 46 in
which the processor is configured to differentially compare
biopotential Voltages at more than one acquisition site on a
tissue by selectively using biopotential acquisition leads as
reference leads to the biopotential amplifier or as differential
leads to the biopotential amplifier.
51. A tissue stimulation apparatus as set forth in claim 1 in
which the tissue stimulation apparatus includes an impedance
testing circuit configured to monitor the impedance of tissues,
the apparatus being configured to determine parametric val
ues of an electrical tissue stimulation signal in response to
tissue impedance data acquired by the impedance testing

52. A tissue stimulation apparatus as set forth in claim 51 in
which the impedance testing circuit is coupled to the electri
cal stimulation device and a biopotential amplifier of a bio
potential acquisition device and is configured to monitor the
impedance of tissues in contact with at least one ground lead
and at least one biopotential acquisition lead of the biopoten
tial acquisition device and to transfer Such data to the proces
SO.
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53. A tissue stimulation apparatus as set forth in claim 51
further including an external computing device coupled to the
processor and configured to analyze tissue impedance data
and to send corresponding control data to the processor for
altering parametric parameters of electrical tissue stimulation
signals.
54. A tissue stimulation apparatus as set forth in claim 1 in
which the tissue stimulation apparatus includes an impedance
testing circuit that is coupled with the biopotential amplifier
ofa biopotential acquisition device and is configured to moni
tor biopotential Voltage integrity.
55. A tissue stimulation apparatus as set forth in claim 54 in
which the tissue stimulation apparatus is configured to indi
cate to a user when good biopotential Voltage integrity is
achieved.
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56. A tissue stimulation apparatus as set forth in claim 54 in
which the tissue stimulation apparatus is configured to gen
erate an alert when biopotential Voltage integrity is lost.
57. A tissue stimulation apparatus as set forth in claim 1 in
which the tissue stimulation apparatus comprises:
a Sensor Set,

an independent biopotential Voltage measurement appara
tus; and
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an adjunct electrical stimulation apparatus operatively
connected between the sensor set and the independent
biopotential Voltage measurement apparatus, opera
tively coupled to the electrical stimulation device, and
configured to transmit to the sensor set electrical tissue
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stimulation signals received from the electrical stimula
tion device, to transmit biopotential Voltage from the
sensor set to the independent biopotential Voltage mea
Surement apparatus, and to receive control signals from
a processor of the electrical stimulation device.
58. A tissue stimulation apparatus as set forth in claim 57 in
which the biopotential measurement apparatus is an EEG
measurement apparatus and the sensor set is an EEG sensor
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set by selective Switching via the adjunct Switching con
trol operated by the processor when tissue stimulation is
required; and
to couple an electrode of the sensor set to ground by selec
tive Switching via the adjunct Switching control operated
by the processor when grounding of an electrode is
desired.

Set.

59. A tissue stimulation apparatus as set forth in claim 57 in
which the sensorset comprises at least one electrode and a cap
configured to position the at least one electrode and to be
worn by a Subject.
60. A tissue stimulation apparatus as set forth in claim 57 in
which in which the adjunct electrical stimulation apparatus

10

device; and
15

includes:

an adjunct Switching control operatively coupled to the
processor of the electrical stimulation device;
a plurality of adjunct Switching circuits operatively
coupled to the adjunct Switching control, to the electrical
stimulation device, to the independent biopotential mea
Surement apparatus, and to respective electrodes of the
sensorset; and

the processor and adjunct Switching control are configured
to provide selectable conduction pathways for tissue
stimulation signals between the electrical stimulation
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device and the electrodes of the sensorset, and for bio

potential voltages between the electrodes of the sensor
set and the biopotential Voltage measurement apparatus.
61. A tissue stimulation apparatus as set forth in claim 60 in
which in which the processor and adjunct Switching circuits
are configured to provide selectable conduction pathways
between the electrodes of the sensor set and a ground.
62. A tissue stimulation apparatus as set forth in claim 57 in
which the adjunct electrical stimulation apparatus includes:
a ground Switching circuit operatively coupled to the pro
cessor of the electrical stimulation device, to the biopo
tential amplifier, and by conduction paths to respective
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electrodes of the sensorset:

a plurality of inductors operatively coupled to the electrical
stimulation device and to the conduction paths; and
the processor and ground Switching circuit are configured
to provide selectable conduction pathways for tissue
stimulation signals between the electrical stimulation
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device and the electrodes of the sensorset, and for bio
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potential voltages between the electrodes of the sensor
set and the biopotential Voltage measurement apparatus.
63. A tissue stimulation apparatus as set forth in claim 62 in
which the processor and ground Switching circuit are config
ured to provide selectable conduction pathways between the
electrodes of the sensor set and a ground.
64. A tissue stimulation apparatus as set forth in claim 60 in
which the adjunct electrical stimulation apparatus includes at
least one Switching control conductor electrically coupled to
an adjunct Switching circuit and configured to determine the
state of the adjunct Switching circuit and a conduction path
provided to a corresponding electrode of the sensorset.
65. A tissue stimulation apparatus as set forth in claim 57 in
which the processor of the electrical stimulation device and
the adjunct Switching control are configured to:
direct biopotential voltage from selected electrodes of the
sensorset to the biopotential measurement apparatus by
Selective Switching via the adjunct Switching control
operated by the processor when a biopotential Voltage
measurement is required;
to direct a tissue stimulation signal from the electrical
stimulation device to selected electrodes of the sensor

66. A tissue stimulation apparatus as set forth in claim 1
and further comprising:
a mobile apparatus carrying the electrical stimulation
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a material Supplies storage and use apparatus carried by the
mobile apparatus and configured to carry consumable
Supplies for use in administering tissue stimulation sig
nals to a Subject.
67. A tissue stimulation apparatus as set forth in claim 66 in
which the material Supplies storage and use apparatus is con
figured to carry any number of consumable Supplies selected
from the group of Supplies consisting of conductive pastes,
conductive gels, cleaning materials, cleaning agents, and Sup
porting materials.
68. A tissue stimulation apparatus as set forth in claim 66 in
which the material Supplies storage and use apparatus com
prises a plurality of receptacles configured to store any num
ber of items selected from the group of items consisting of a
waste, conductive gel, conductive paste, cleaning materials,
alcohol, Supporting materials, and electrodes.
69. A tissue stimulation apparatus as set forth in claim 66 in
which the material supplies storage and use apparatus
includes an electrode storage receptacle configured to store
and block light from reaching lead electrodes comprising
photosensitive materials.
70. A tissue stimulation apparatus as set forth in claim 66 in
which the tissue stimulation apparatus includes one or more
sensors carried by the material Supplies and use apparatus and
configured to sense the quantities of materials stored in recep
tacles of the material Supplies storage and use apparatus.
71. A tissue stimulation apparatus as set forth in claim 66 in
which the tissue stimulation apparatus includes an external
computing device coupled to the one or more sensors and
configured to manage inventory in response to signals
acquired from the one or more sensors.
72. A tissue stimulation apparatus as set forth in claim 71 in
which the tissue stimulation apparatus is configured to gen
erate an alert when inventory of any material reaches a pre
determined low point.
73. A tissue stimulation apparatus as set forth in claim 71 in
which the tissue stimulation apparatus is configured to order
materials necessary to replenish inventory when a predeter
mined low point is reached.
74. A tissue stimulation apparatus as set forth in claim 71 in
which the tissue stimulation apparatus is configured to order
materials by interfacing with a communications network.
75. A tissue stimulation apparatus as set forth in claim 66 in
which the electrical stimulation apparatus is configured to
provide stimulation through composite stimulation leads, the
composite stimulation leads comprising a combination of
stimulation leads and ground leads.
76. A tissue stimulation apparatus as set forth in claim 75 in
which the composite stimulation leads include external
stimulation device cables.
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